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Frank Cameron Cackowski, PhD 
University of Pittsburgh, 2009
 
 
Osteoclastogenesis and angiogenesis are correlated in bone during physiological and 
pathological processes including development, fracture healing, bone metastases and 
inflammatory bone disease.  However, it is unclear if and how these processes are linked.  This 
dissertation investigates a possible causative role for osteoclasts in bone angiogenesis.  First, 
changes in osteoclast formation and activity affected angiogenesis in a parallel fashion.  
Osteoclast inhibition decreased angiogenesis, while osteoclast stimulation increased 
angiogenesis in fetal mouse metatarsal explants.  Likewise, osteoclast stimulation also increased 
angiogenesis in mouse calvaria in vivo, thus showing that osteoclasts and angiogenesis are 
linked.  Further studies were conducted to determine the mechanism by which osteoclasts may 
increase angiogenesis.  Angiogenic factor expression by osteoclasts was analyzed by reverse-
trancriptase PCR and Q-PCR angiogenesis arrays of human bone marrow osteoclasts.  MMP-9 
was the most highly expressed osteoclast angiogenic factor at the mRNA level.  Because MMP-9 
is important for osteoclast and blood vessel invasion of the growth plate and fracture calluses, the 
role of MMP-9 in osteoclast stimulated angiogenesis was studied in depth.  Osteoclast 
stimulation with RANKL or PTHrP failed to stimulate angiogenesis in MMP-9-/- mouse calvaria 
or metatarsal explants.  Surprisingly, osteoclast stimulation was dramatically blunted in MMP-9-
/- calvaria or metatarsal explants.  However, the number of vessels per osteoclast was not 
different between WT and MMP-9-/- mice, indicating that osteoclasts lacking MMP-9 do not 
have an intrinsic angiogenic defect.  Further, bone marrow cultures from WT and MMP-9-/- mice 
formed similar numbers of osteoclasts, demonstrating that osteoclast differentiation or precursor 
number is not responsible for the inability of PTHrP or RANKL to increase osteoclastogenesis in 
MMP-9-/- mice.  These results suggest that MMP-9 is important for osteoclast-stimulated 
angiogenesis by affecting the number of osteoclasts at the angiogenic site due to its previously 
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reported effects on osteoclast migration.  These studies greatly increase our understanding of 
angiogenesis in bone and suggest an important role for osteoclasts in angiogenesis during bone 
development, fracture healing, bone metastasis, inflammatory bone diseases and the potential 
effects of osteoclast inhibitory agents on angiogenesis.                       
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1.0  INTRODUCTION 
1.1 DISSERTATION GOALS AND OBJECTIVES 
Angiogenesis is critical to normal bone development and physiology and disease processes 
involving bone, such as rheumatoid arthritis and bone metastases.  There are many situations 
where angiogenesis is correlated with osteoclastogenesis including endochondral ossification in 
development, myeloma and other bone metastases, rheumatoid arthritis and Paget’s disease of 
bone.[1-3]  Despite these observations, only two Medline-indexed studies have investigated in 
depth whether osteoclasts stimulate angiogenesis, and their results were conflicting.[4, 5]  
Therefore, the role that osteoclasts play in angiogenesis in normal physiology and inflammatory 
bone disease is unclear.  Because of the role that osteoclasts may play in these processes I have 
undertaken the required studies to test the hypothesis that; Osteoclasts stimulate angiogenesis 
in the bone microenvironment by secreting factors that directly or indirectly increase new 
vessel formation (Figure 1.1).    
A major goal of this dissertation was to select models that would most accurately 
determine if and how osteoclasts stimulate angiogenesis.  As has been suggested by Tanaka et al, 
osteoclasts may stimulate angiogenesis by secretion of an angiogenic factor such as osteopontin, 
which acts directly on endothelial cells (mechanism #1).  Other reasons suggesting that direct 
stimulation of angiogenesis by osteoclasts may occur include; their secretion of several 
angiogenic factors, and well known direct stimulation of angiogenesis by the closely related cell 
type, the macrophage.[6-9]  To model such a mechanism in vitro, I conducted experiments 
testing the capacity of purified osteoclast culture conditioned media to stimulate tube formation 
of endothelial cells.  Literature supporting this mechanism is discussed in sections 1.2.3.3 and 
1.3.2. 
Alternatively, osteoclasts may stimulate angiogenesis by more complicated mechanisms, 
including release of angiogenic factors from bone or marrow extra-cellular matrices (mechanism 
#2, literature discussed in section 1.2.3.2), or by induction of angiogenic factor secretion by cell 
types such as osteoblasts (mechanism #3, literature discussed in section 1.3.2).  There are several 
reasons that support such mechanisms.  Release of growth factors, especially TGF-β, from bone 
matrix by osteoclasts is well documented.[10, 11]  The matrix metalloproteinase MMP-9 is 
highly expressed by osteoclasts and is used by macrophages or tumor cells to stimulate 
angiogenesis by releasing VEGF from matrix.[12, 13]  Further, MMP-9-/- mice have delayed 
blood vessel invasion into the metaphyseal growth plate, which would be expected if osteoclasts 
stimulate angiogenesis by secreting MMP-9.[14]  Alternatively (mechanism #3), osteoblasts are 
well known to stimulate angiogenesis through secretion of VEGF, and osteoclast formation 
induces a coupled increase in osteoblast formation and activity.[15, 16]  Therefore, osteoclasts 
may stimulate angiogenesis through interactions with osteoblasts.  To model in vitro the possible 
ways that osteoclasts could stimulate angiogenesis, including these complex mechanisms, I used 
a bone organ culture system, the fetal mouse metatarsal angiogenesis assay, in which endothelial 
cell tubes grow out from explants of mouse metatarsals, rather than purified populations of 
various cell types.[17].  I then tested the relevance of the in vitro findings in vivo.  
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 Figure 1.1.  Hypothesis 
Osteoclasts stimulate angiogenesis in the bone microenvironment by secreting factors that directly or 
indirectly increase vessel formation.  Osteoclasts may stimulate angiogenesis by (1) direct action of an angiogenic 
factor on vessels, (2) release of an angiogenic factor for calcified or non-calcified matrix and (3) induction of an 
angiogenic factor in second cell type such as an osteoblast or stromal cell.      
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1.2 BIOLOGY OF OSTEOCLASTS AND BONE ANGIOGENESIS 
 
1.2.1 Osteoclast Biology 
1.2.1.1 Osteoclast Differentiation 
After almost three decades of intensive study, the cellular origins of the osteoclast (OCL) are 
clear (Figure 1.2).  OCLs are derived from hematopoietic stem cells, which subsequently form 
common myeloid precursors and granulocyte-macrophage precursors (CFU-GM).[18, 19]  CFU-
GM can further differentiate into granulocyte precursors or macrophage / osteoclast / dendritic 
cell common precursors (MODP), which are also referred to as early OCL precursors.[20, 21]  
These cells are c-Fms+ (M-CSF receptor) and RANK-.  M-CSF induces the expression of RANK 
(RANKL receptor) in these cells, thus forming late OCL precursors (Although different authors 
refer to different cell types as early and late OCL precursors.[20])  Late OCL precursors form 
committed precursors, which than fuse to form mature OCLs in the presence of RANKL or 
macrophages in the absence of RANKL.[21]  In bone RANKL ligand signaling is regulated by 
the balance of RANKL and its decoy receptor, osteoprotegerin.[22]  The capability of early OCL 
precursors to form dendritic cells or osteoclasts was first shown by Miyamoto et al.[23]  In this 
study, M-CSF inhibited the formation of dendritic cells and promoted OCL differentiation from 
early OCL precursors by induction of c-fos, whereas GM-CSF was shown to promote dendritic 
cell differentiation from early OCL precursors by inhibiting expression of c-fos.  There remains 
some degree of plasticity among the cell types derived from early OCL precursors.  Rivollier et 
al showed that immature dendritic cells can transdifferentiate into functional OCL in the 
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presence of M-CSF and RANKL.[24]  Conversely, several studies have found that differentiated 
macrophages can also transdifferentiate into OCLs.[25-27]          
 
Figure 1.2.  Osteoclast differentiation 
 
As described above, M-CSF and RANKL are central regulators of OCL differentiation.  
However, multiple factors can also regulate OCL differentiation, only some of which will be 
described here.  Many inflammatory cytokines, in particular TNF-α, stimulate OCL formation.  
TNF-α is a potent stimulator of OCL formation, primarily through induction of M-CSF and 
RANKL in bone marrow osteoblasts and stromal cells.[28]  TNF-α also acts directly on OCL 
precursors to induce OCL formation.  However, it is unclear if TNF-α coupled with M-CSF are 
sufficient to induce OCL formation, or whether sub-optimal doses of RANKL are also required.  
Several studies have found that TNF-α and M-CSF are sufficient to induce OCL formation from 
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precursors.[29-31]  However, in a study where the authors used highly purified cell populations 
to eliminate exposure of OCL precursors to paracrine-produced RANKL, sub-optimal doses of 
RANKL were required for TNF-α to stimulate osteoclastogenesis[32].  In agreement with this 
observation that TNF-α requires RANKL to stimulate osteoclastogenesis, transgenically 
expressed TNF-α was not able to rescue OCL formation in a RANK (RANKL receptor) null 
mouse.[33]  Although TNF-α by itself may or may not be sufficient to induce OCL 
differentiation in combination with M-CSF, the addition of other cytokines to M-CSF and TNF-α 
can induce OCL in a RANK independent manner.  Kim et al showed that TNF-α and M-CSF can 
induce OCL formation in cells from a RANK-/- mouse if the precursors are first incubated with 
M-CSF and TGF-β.   Even if TNF-α and M-CSF are sufficient to induce OCL formation, the 
OCLs that are formed do not resorb bone efficiently.  Addition of IL-1α was required for 
comparable resorption as RANKL derived OCLs.[29-31]   
The inflammatory cytokine IL-1 likewise stimulates OCL formation both indirectly and 
directly, although it was first believed that its effects were all indirect.  Induction of IL-1 is 
required for stimulation of RANKL expression in stromal cells by TNF-α, and is required for 
maximal OCL formation in whole bone marrow cultures stimulated by M-CSF and RANKL.[34, 
35]  IL-1 also can stimulate OCL formation by inducing production of PGE2 in osteoblasts.[36]  
IL-1 induces the fusion of fully differentiated committed precursors (pre-OCLs) and can 
stimulate OCL formation by acting directly on OCL precursors in the presence of permissive 
levels of RANKL.[34, 37]   
Like the inflammatory cytokines, LPS also stimulates OCL differentiation as well as 
survival.  These effects of LPS on survival are most primarily due to stimulation of osteoblasts 
through toll-like receptors to increase RANKL production.[38]  LPS stimulates OCL survival 
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through TLR4, but this was not due to production of the inflammatory cytokines TNF-α, IL-1β, 
and IL-6.[39]  This contrasts with the effects of LPS on bone marrow macrophages, where 
inflammatory cytokines are released in response to LPS.  These results suggest that the responses 
of OCLs and macrophages to LPS are different.       
The inflammatory cytokine IFN-γ also stimulates OCL formation, although not directly.  
The direct effect of IFN-γ upon OCL precursors is to inhibit OCL formation by inducing 
degradation of the RANK adaptor protein TRAF6.[40]  However, the net effect of IFN-γ in vivo 
is to increase OCL formation through activation of T cells which increase secretion of RANKL 
and TNF-α.[41]   
Like IFN-γ, TGF-β also has competing effects on OCL formation.  The direct action of 
TGF-β upon OCL precursors is to stimulate OCL formation.  Endogenous TGF-β is required for 
osteoclastogenesis stimulated by M-CSF and RANKL and addition of TGF-β increases 
osteoclastogenesis stimulated by TNF-α.[42, 43]  Further, TGF-β also blocks the direct 
inhibitory effect of IFN-γ upon OCL formation.[44]  However, TGF-β also acts to decrease OCL 
formation by increasing the ratio of osteoprotegrin (OPG – a RANKL decoy receptor) to 
RANKL produced by osteoblasts.  Both osteoblast OPG is increased and RANKL is decreased 
by TGF-β.[45, 46]   
Unlike inflammatory cytokines, which in general stimulate OCL differentiation, anti-
inflammatory (TH2) cytokines usually inhibit OCL formation.  In contrast to their effects on 
OCL, anti-inflammatory cytokines induce a pro-angiogenic state in macrophages.  IL-10 inhibits 
OCL formation, possibly by down-regulating NFATc1 in OCL precursors.[47]  IL-13 and IL-4 
also inhibit OCL formation, both by direct effects on OCL precursors and by increasing OPG 
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production by osteoblasts.  IL-4, like IL-10, likewise down-regulates NFATc1 in OCL 
precursors.[48]   
 
1.2.1.2 Osteoclast Activation and Resorption   
Once formed, OCLs must be exposed to the proper soluble and matrix bound signals to resorb 
bone.  To resorb bone, OCLs must be motile, adhere to bone, polarize their cytoplasm and isolate 
the section of bone to be resorbed (ruffled border) from the external environment so that their 
secreted proteases and acid are localized.  Thus, “activation” of OCL combines several distinct 
but related processes.[49]  Two organelles are required for a resorbing OCL; the ruffled 
membrane and the actin ring.  The ruffled membrane is the portion of the OCL membrane 
adjacent to bone.  It contains the machinery required for acidification of the resorption space and 
is formed by fusion of acidified vesicles with the bone-opposed surface.  The actin ring, also 
known as the “sealing zone”, is made up of polymerized actin and surrounds the resoption space.  
It is necessary but not sufficient for OCLs to resorb bone.[50]   
Interaction with the extra cellular matrix is central to the formation of a resorbing OCL.  
αvβ3 integrin is required for resorptive OCLs but not for OCL formation as illustrated by the β3 
knockout mouse.[51]  β3-/- mice actually have more OCLs in vivo but are osteopetrotic (excess 
bone).  β3-/-  OCLs fail to undergo the cytoskeletal organization characteristic of resorbing OCLs; 
they fail to form actin rings when isolated from bone and form abnormal ruffled membranes in 
vivo.   
The mechanism by which αvβ3 ligation leads to OCL cytoskeletal reorganization and 
resorption is beginning to be delineated.  Src plays a central role in this process as shown by the 
suprising finding that the predominant phenotype of src-/- mice is osteopetrosis.[52]  Src-/- mice 
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have an almost identical phenotype to β3-/- mice; increased OCL numbers, but lack of resorption 
pits and ruffled membranes are found in vivo.[53]  A study of the src family kinase syk, using 
either global syk-/- or mice lacking syk in hematopoietic cells provided a linear pathway for β3 
stimulation of OCL resorption.[54]  Syk-/- mice are osteopetrotic.  OCLs in syk hematopoietic 
chimeras are smaller than wt and not juxtaposed to bone.  The authors propose a pathway where 
αvβ3 ligation leads to Src recruitment and phosphorylation.  Src then associates with and 
phosphorylates syk, which requires the ITAM proteins Dap12 and FcRγ.  Phosphorylation of the 
guanine nucleotide exchange factor Vav3 required αvβ3 ligation and Syk kinase activity.  Vav3, 
as well as the GTPase Rac1, are required for a normal bone phenotype and OCL resorption and 
actin ring formation.[55]  M-CSF in addition to its role in stimulating OCL formation can 
cooperate with αvβ3 to induce OCL cytoskeletal organization.  High doses of M-CSF (100 ng / 
mL) can compensate for lack of αvβ3 in terms of stimulating OCL formation, but cannot restore 
resorptive ability. [56]          
RANKL, in addition to its central role in OCL differentiation, also stimulates OCL 
activation as shown in cultures of isolated rat OCLs.[57]  Likewise, the osteoclastogenic 
cytokine IL-1 also stimulates OCL cytoskeletal organization and activation.[37]  Both of these 
cytokines stimulate OCL activation through the adaptor molecule TRAF6, although the 
downstream intracellular signaling pathways are unclear.  The TNF receptor associated factor 6 
(TRAF6) binding domain of RANK is required for RANKL induced OCL activation.  A RANK 
mutant that could not bind TRAF6 or mediate RANKL stimulated OCL activation was 
compensated for by addition of IL-1β.[58]  IL-1 induced OCL activation occurs through a 
TRAF6 and c-Src containing complex, suggesting that it cross talks with integrin regulation of 
OCL activation.[59] 
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1.2.1.3 PTH and PTHrP in Bone Remodeling 
The key paracrine factors described above that regulate OCL formation are in turn primarily 
regulated at the whole animal level by endocrine factors including 1,25 dihydroxy vitamin D3 
and parathyroid hormone (PTH).  PTH acts to increase serum calcium by increasing OCL 
formation and activity and 1,25 dihydroxy vitamin D3 synthesis and thus results in increased 
intestinal calcium absorption, increased calcium retention in the kidney, and release of calcium 
from the skeleton by way of osteoclastic bone resorption.  PTH is a peptide hormone, which is 
comprised of 84 amino acids.  It is homologous to a great extent in the N-terminal 13 amino 
acids to parathyroid hormone related peptide (PTHrP).  Both molecules share a common receptor 
(PTHR1) that mediates most of their functions.[60]   
The physiological effects of PTH and PTHrP are complex, as they can affect both OCLs 
and osteoblasts.  Physiologic concentrations of PTH and PTHrP given continuously act in a 
catabolic fashion – to activate OCLs and degrade bone.  This OCL induction is primarily indirect 
– through increased RANKL and decreased osteoportegerin expression in osteoblasts.[61]  
Paradoxically, PTH or PTHrP increase bone mass when given intermittently.  This increase in 
bone mass is primarily due to decreased apoptosis of osteoblasts and reduced adipocytic 
differentiation of the common mesenchymal precursor.[62]    
In contrast to PTH, which functions primarily in adults to maintain calcium homeostasis, 
PTHrP has important roles in development, as was shown in mice lacking PTHrP or PTHR1.[63]  
PTHrP is thought to be most important in development due to its effects on chondrocytes.  
PTHrP-/- mice die post-natally, likely due to asphysxia because of the reduced size of their 
ribcage.[64]  They have shortened epiphyseal cartilages due to reduced chondrocyte 
proliferation, as was demonstrated by reduced thymidine uptake.  In addition, the architecture of 
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the chondrocyte columns is disrupted.[65]  The role of PTHrP in development is likely not 
completely due to signaling through PTHR1, as PTHR1-/- mice have three additional 
abnormalities not formed in the PTHrP-/-; increased osteoblast number, decreased trabecular 
bone formation in the primary spongiosa and delayed vessel invasion into the primary 
ossification center.[66]  The delay in vessel invasion was blunted in mice lacking both PTHrP 
and PTHR1.  The authors thus concluded that PTHrP delayed vessel invasion through a different 
receptor than the classic PTHR1.[66]   
In agreement with this observation, PTHrP has been reported to be anti-angiogenic.[67, 
68]  Full length PTHrP reduced angiogenesis in the chick chrioallantoic membrane and mouse 
matrigel plug angiogenesis assays.  Most of the activity required for PTHrP inhibition of 
endothelial cell migration or angiogenesis in the matrigel plug assay was located in the first 10 
amino acids of the molecule.  PTHrP’s effects on endothelial cell migration required PKA.  This 
is consistent with PTHR1 being responsible for the anti-angiogenic effects of PTHrP.  However, 
a requirement for PTHR1 in PTHrP inhibition of angiogenesis was not shown.  In contrast with 
these data, an earlier report found that PTHrP was pro-angiogenic.[69]  PTHrP knockdown was 
shown to inhibit angiogenesis induced by tumor cells around a diffusion chamber implant.  
PTHrP did not affect endothelial cell migration or survival, but increased capillary tube 
formation on a collagen matrix in a PKA dependent manner.  PTHrP also induces vasodilation 
through a mechanism requiring endothelial cells but not PKA.[70]  Therefore, a possible direct 
role of PTHrP in angiogenesis is unclear.             
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1.2.2 General Angiogenic Mechanisms 
1.2.2.1 Angiogenesis in Biology 
Angiogenesis is the development of new blood vessels from a pre-existing vascular network.  It 
occurs in the embryo after a primitive vascular network is laid down through vasculogenesis, is 
responsible for most post-natal blood vessel formation and is essential for the formation of a 
functional vascular network in the embryo.  Vasculogenesis by contrast is the formation of a 
vascular bed de novo through differentiation of precursors.[71]  The study of angiogenesis is 
primarily concerned with the growth of capillaries from other capillaries or small venules, which 
grow either by sprouting or by insertion of tissue pillars into vessels to form branches 
(intussusception).  Larger vessels grow by circumferential growth rather than by sprouting and 
branching.[72]  Angiogenesis occurs in a limited number of circumstances in normal adults 
including wound healing and the female reproductive organs but is upregulated in disease states 
such as cancer and rheumatoid arthritis.[73-76]  Because of this downregulation of angiogenesis 
in normal post-natal physiology, its inhibition is an attractive therapeutic approach.[76]  Indeed, 
the number of investigators involved in angiogenesis research has ballooned in recent decades.  
At this writing, there were over 42,000 PubMed citations on angiogenesis. 
1.2.2.2 Cellular Mechanisms of Angiogenesis 
A discussion of bone angiogenic mechanisms first requires an understanding of the cells 
involved in angiogenesis.  Much attention in angiogenesis is focused on the vessel lining cell, the 
endothelial cell, but other cell types also play important roles.  Most vessels are surrounded by 
cell types generally referred to as mural cells; pericytes on capillaries and vascular smooth 
muscle cells on larger vessels.[72]  Angiogenesis occurs by two principle microanatomic modes, 
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sprouting and intussusception.  For many years sprouting was for the most part synonymous with 
angiogenesis itself.[77]   
In sprouting angiogenesis, an endothelial cell selected to form a new sprout, called a tip 
cell, is identified.  The basement membrane is degraded and the tip cell migrates outward.  The 
tip cell is followed by stalk endothelial cells, which proliferate to lengthen the stalk.  The tip cell 
eventually encounters an appropriate tip cell from another sprout and thus forms a linkage.  The 
endothelial cells reorganize to form a lumen and blood flow begins.  Finally the vessel matures, 
with the stabilization of endothelial cell contacts, recruitment of mural cells and formation of a 
basement membrane.[72, 78] 
The other, less discussed and understood, mode of angiogenesis is intussusception.  In 
intussusception, pillars are inserted into capillaries to form new branches.  This allows additional 
complexity and better perfusion to an existing vascular bed.  Unlike sprouting, intussusception 
does not allow capillaries to extend into previously avascular areas.  This reorganization is 
accomplished in the continuous presence of blood flow, unlike sprouting angiogenesis.  
Proliferation of endothelial cells, while involved is somewhat less important than in sprouting 
angiogenesis.[77, 78]   
Bone marrow endothelial cell precursors make important contributions to blood vessel 
growth, though they may not act through truly angiogenic mechanisms.  Technically speaking, 
vascular growth by endothelial precursor cells is vasculogenesis and not angiogenesis because it 
involves differentiation from precursors rather than sprouting or intussusception from existing 
capillary beds.  In addition, this growth is usually circumferential rather than sprouting or 
intussusceptive.[72]  As an illustration that bone marrow endothelial cell precursors contribute to 
vasculogenesis rather than angiogenesis, bone marrow endothelial precursor cells were shown to 
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form blood island structures reminiscent of the blood islands formed during vasculogenesis in 
the embryo.[79]  However, there has been some evidence that endothelial precursor cells can be 
incorporated into capillaries, which suggests they contribute to sprouting angiogenesis as 
well.[80, 81]     
1.2.2.3 Key Regulators of Angiogenesis 
The most well known and perhaps most important family of angiogenic stimulatory molecules 
are the vascular endothelial growth factors (VEGFs).  This large family is the product of five 
different genes in mammals (VEGFA (or simply VEGF), VEGFB, VEGFC, FIGF ( VEGFD), and 
PGF (PlGF) ), many of which have splice isoforms.[82, 83]  Each VEGF form exerts its effects 
on blood vessel angiogenesis or lymphangiogenesis through binding to one or more of the VEGF 
receptor tyrosine kinases VEGFR1 (flt-1), R2 (flk-1 / KDR) and R3 (flt-4).[83]  VEGFR2 is 
principally involved in blood vessel angiogenesis, while VEGFR3 is principally involved in 
lymphangiogenesis.  The contribution of VEGFR1 to angiogenesis is more complex.  VEGFR1, 
but not its kinase domain, is required for embryonic angiogenesis.  VEGFR1-/- embryos die with 
disorganized vessels, which suggests that VEGFR1 acts as a decoy for VEGF-A during 
development.  However, the kinase domain of VEGFR1 is required for post-natal 
angiogenesis.[84, 85] 
VEGF-A (or simply VEGF) is alternatively spliced to yield as many as six isoforms, 
which add another layer of complexity to angiogenic regulation.[82, 86]  The longer forms bind 
heparan sulfate proteoglycans, while the shortest form – VEGF121 (or VEGF120 in mice) is freely 
diffusible.  The various VEGF isoforms have different biological functions.  The matrix bound 
forms are required for proper vessel structure.  In a mouse expressing VEGF120 (VEGF120/120)but 
none of the other VEGF isoforms, there are fewer, but more dilated vessels.  The defect was due 
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to branch formation rather than proliferation.[87]   A similar phenotype of the VEGF120/120 mouse 
with fewer but larger vessels was observed in bone.  Endochondral ossification is delayed in a 
phenotype resembling that of the MMP9-/- mouse (discussed below) [88].  In addition to 
molecular genetic regulation, shorter forms of VEGF can be generated by MMPs rather than by 
alternative splicing, with similar biological effects.[89] 
The angiopoietin family makes essential but complex contributions to angiogenesis.  The 
family consists of three ligands; Ang-1 and Ang-2 in most species, as well as Ang-3 in mouse 
and Ang-4 in human.[90]  The angiopoietins exert their biological functions by binding to the 
Tie2 tyrosine kinase receptor.  Ang-1 acts as an agonist, while Ang-2 acts as a receptor 
antagonist.[91, 92]  Although they are orthologs, Ang-3 and Ang-4 have opposite effects on 
Tie2, with Ang-3 acting as an antagonist and Ang-4 acting as an agonist.[90]  Stimulation of 
Tie2 induces maturation of vessels, including endothelial cell stabilization and mural cell 
recruitment.  This was first illustrated in a knockout of the Ang-1 gene, where knockout vessels 
had less spread endothelial cells and lacked mural cells.[93]  Ang-1-/- mice are embryonic lethal 
and die due to cardiovascular abnormalities.  Surprisingly, Ang-2-/- mice are born alive but die by 
two weeks of age of lymphatic abnormalities.  Post-natal blood vessel angiogenesis is also 
inhibited in Ang-2-/- mice.[94]  These and other observations have led to the following classic 
model of the role of angiopoietins in post-natal angiogenesis:  Ang-2 is required for initiation of 
angiogenesis by loosening endothelial and mural cell attachements.  In the presence of VEGF, 
Ang-2 leads to angiogenesis, whereas in its absence Ang-2 leads to vessel regression.  Ang-1 is 
required for vessel maturation.[95]            
Another family of molecules with affects on both endothelial and mural cells are the 
TGF-βs.  The TGF-β superfamily includes not only the 3 TGF-β forms, but also bone 
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morphogenetic proteins, activins, and inhibins.  Furthermore, the TGF-β family members exert 
their influences through binding to three different classes of receptors; type I receptors Alk1 and 
Alk5, the type II receptor TGFβRII, and the type III receptor endoglin, which influences the 
interaction of type I and type II receptors.  Perhaps not-surprisingly given the many molecules 
involved, the effects of TGF-β on angiogenesis are complex, with many cell and tissue 
dependent effects.[96]   
 Because deletion of TGF-β signaling components such as Alk-1 results in lethality from 
vasculogenic defects at approximately E10.5, TGF-β is obviously important for vessel formation 
or function.[97]  Vessels in TGF-β signaling component knockout mice are hyperdilated and 
have abnormal mural cell recruitment, suggesting that TGF-β is involved in vessel maturation.  
Consistent with a role in vessel stabilization, TGF-β increases endothelial cell expression of 
proteins important for interaction with the basement membrane.[98]  
 However, the effect of TGF-β signaling on other endothelial cell functions is not as clear.  
TGF- β signals through heterodimerization of type I and type II receptors.  Studies using 
constitutively active type I receptors in endothelial cells have yielded conflicting results.  Studies 
using different sources of endothelial cells are in agreement that constitutively active Alk-5 
inhibits endothelial cell proliferation, sprouting or migration.[99-102]  However, while most 
studies have found that Alk-1 activation also inhibits endothelial cells, one study using mouse 
embryonic endothelial cells, found that constitutively active Alk-1 stimulated endothelial cell 
migration.[102]  TGF-β’s effects on angiogenesis are likely to vary depending on cellular or 
tissue context.  Such inhibitory effects of TGF-β upon endothelial migration are consistent with 
it playing a role in the maturation phase of angiogenesis, as was first observed in mice lacking 
TGF- β signaling components.     
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1.2.3 Normal Bone Angiogenesis 
1.2.3.1 Vascular Structure of Adult Bone 
OCLs are in close proximity to capillaries and are thus in a good position to signal to blood 
vessels.  The vasculature of adult long bones has a complex structure with extensive 
anastamoses.  Arterial blood supply is derived from six sources; proximal and distal epiphyseal 
arteries, proximal and distal metaphyseal arteries, diaphyseal nutrient arteries and periosteal 
arteries.  Venous drainage is paired with the corresponding arteries including the central venous 
sinus which is drained by the nutrient vein[103].  Bone marrow sinusoidal vessels are part of the 
reticuloendothelial system and have structures very different than bone marrow arterial or 
capillary vessels, or most vessels in the body.  The surface phenotype of bone marrow sinusoidal 
endothelial endothelial cells is also different than most endothelial cells, with reduced or absent 
CD31 expression.[104]   
The microanatomy of capillaries is characterized by their close association with bone 
cells.  Cortical bone is organized into Haversian systems where bone is concentrically organized 
around a neurovascular bundle which is lined by osteoblasts and osteoprogenitors.  Blood vessels 
are closely associated with resorption of cortical bone.  OCLs form a resorption cavity or cutting 
cone, into which a capillary then invades.[105]  Likewise, capillaries are also closely associated 
with bone cells in trabecular bone.  Long ago, Burkhardt et al showed that capillaries are closely 
associated with the cells lining trabeculae and observed that microvessel density in bone is 
associated with increased remodeling.[106]  More recently the existence of a microstructure in 
trabecular bone termed a bone remodeling compartment (BRC), has been proposed. (Figure 
1.3)[107]  In this model, the OCLs and osteoblasts involved in bone remodeling are enclosed in a 
dome of osteoblast-like cells that are in close association with a capillary.  The interior of the 
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BRC may or may not be in continuity with the circulation.  Another model proposed for the 
relationship of osteoblasts, OCLs and capillaries is the “basic multicellular unit” (BMU) (Figure 
1.4).  In the BMU model, in both trabecular and cortical bone, osteoblasts and OCLs are located 
in close proximity to a blood vessel, except that the lining layer of osteoblast-like cells is not 
present.[16]  Therefore, in both cortical and trabecular bone, osteoclasts are closely opposed to 
vessels and have the potential to regulate blood vessel formation by paracrine mechanisms. 
 
 
Figure 1.3.  Bone remodeling compartment model 
Illustration of the bone remodeling compartment model of bone resorption.  Bone at bottom, marrow space 
at top of image.  OBL; osteoblasts.  Adapted from Hauge et al.[107] 
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Figure 1.4.  Basic multicellular unit model 
Illustration of the basic multicellular unit (BMU) model of bone resorption in cortical bone.[16]  Note that 
the endothelial cell lined vascular sinus is closely opposed to both osteoblasts and osteoclasts.     
 
1.2.3.2 Regulation of Bone Angiogenesis by Osteoblasts and Stroma 
Most cells in bone have a regulatory role in angiogenesis, many through production of 
angiogenic factors.  I discuss here the mechanisms used by osteoblasts to stimulate angiogenesis, 
because of the possibility that OCLs stimulate angiogenesis through interaction with osteoblasts 
or stroma, and that the angiogenic factors acting directly on endothelial cells may be non OCL-
derived.  OCLs may stimulate angiogenesis through induction of angiogenic factor secretion in 
osteoblasts, such as the ability of TGF-β, which can be released from matrix by OCLs, to 
stimulate osteoblast VEGF expression.[108, 109]  Alternatively, OCLs may stimulate 
angiogenesis by way of osteoblasts by increasing osteoblast formation.  Except in a small 
number of pathologies, OCL and osteoblast formation are coupled.  Increased OCL formation or 
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activity leads to increased osteoblastic formation, and possible effects on angiogenesis.[16]  To 
provide a summary of angiogenesis regulation in bone, several of the angiogenic factors 
expressed by bone cells are listed in Table 1.1.   
Most osteoinductive factors, many of which are derived from endothelial cells, are 
capable of inducing the production of VEGF by osteoblasts.[110]  For example, BMP-2  
stimulates angiogenesis by inducing osteoblast VEGF production.[111]  BMP-2 also stimulates 
production of the VEGF family member PlGF in mesenchymal stem cells.[112]  Likewise, IGF-
1 and prostaglandins also upregulate osteoblast VEGF expression.[113, 114]  The endothelial 
derived osteogenic molecule angiotensin-II has also been shown to up-regulate osteoblast 
VEGF.[115] Endothelin-1, although it is an endothelial cell derived osteogenic factor, has been 
reported to down-regulate osteoprogenitor VEGF expression in vitro in a fetal rat calvarial 
culture model.[116]  However, this discrepancy may have occurred because the cells were not 
mature osteoblasts.  Consistent with this hypothesis, the inhibitory effect of endothelin-1 was 
less pronounced after longer culture periods.   
Like many other cell types, osteoblasts increase production of angiogenic factors in 
response to hypoxia.  Hypoxia upregulates production of VEGF and causes nuclear accumulation 
of HIF-1α in an osteoblast derived cell line.  In vitro angiogenesis stimulated by these cells was 
reduced by antibodies to bFGF and VEGF.[117]  Wang et al showed that osteoblast derived 
VEGF induced by HIF-1α and HIF-2α contributed to developmental angiogenesis and bone 
formation in mice.[15]  HIF isoforms may also play a role in osteoblasts’ contribution to 
angiogenesis stimulated by other processes.  For example, HIF-1α was reported to be important 
in shock wave stimulated osteoblast VEGF expression.[118]  
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 Table 1.1.  Expression of pro- angiogenic factors by bone cells 
Cell Molecule Reference 
Osteoclast VEGF (mouse) 
VEGF (neonatal 
human) 
IL-8 
Osteopontin 
bFGF 
PDGF 
HGF 
Angiopoietin-1 
Angiopoietin-2 
[119] 
[120] 
[121] 
[122] 
[6] 
[6] 
[123] 
[120] 
[120] 
Bone marrow stromal 
cells 
VEGF 
b-FGF 
[124] 
[125] 
Osteoblasts OPN 
VEGF 
Angiopoietin-1 
Angiopoietin-2 
IL-8 
PDGF 
HGF 
bFGF 
[122] 
[119] 
[120] 
[120] 
[126] 
[127] 
[128] 
[129] 
 
 
Table 1.2.  Regulation of osteoblast angiogenic factor production 
Regulator Direction of 
regulation 
Angiogenic 
factor induced 
Reference 
BMP-2 
IGF-1 
Prostaglandins 
HIF-1α, HIF-
2α 
Shock waves 
PDGF-BB 
TGF-β 
↑ 
↑ 
↑ 
↑ 
↑ 
↑ 
↑ 
VEGF [111] 
[113] 
[114] 
[15] 
[118] 
[130] 
[108] 
bFGF ↑ HGF [128] 
TNF-α and 
IFN-γ 
↓ Angiopoietin-
1 
[131] 
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 Osteoblasts may also stimulate angiogenesis by various other mechanisms.  Following 
are examples from the literature.  RANKL, which is primarily derived from osteoblasts, can 
increase angiogenesis as well as vascular permeability in vitro and in vivo in matrigel plug and 
chick chrioallantoic membrane in vivo models.[132, 133]  VEGF was reported to increase the 
expression of RANK by endothelial cells and their angiogenic response to RANKL.[134]  
However, this series of papers used high (μg/mL) RANKL concentrations, thereby calling into 
question the physiological relevance of RANKL stimulated angiogenesis.  In contrast, other 
investigators reported that RANKL inhibits angiogenesis in vitro.[135]  In addition, studies 
reported that the osteoblast derived RANKL decoy receptor osteoprotegerin stimulated 
angiogenesis through endothelial cell apoptosis induced by TRAIL.[135, 136]  Therefore, a 
possiblility of direct effects for the osteoblast derived regulatory molecules RANKL and 
osteoprotegerin remains unresolved. 
Additional possible mechanisms used by osteoblasts to stimulate angiogenesis include the 
following.  PDGF-BB was shown to induce VEGF production in neonatal rat calvarial 
osteoblasts.[130]  bFGF induced HGF expression in fetal rat calvariae derived osteoblasts, which 
was lessened by cortisol.[128]  TGF-β upregulated VEGF expression in an osteoblastic cell line 
involving signaling through p38 and Erk 1/2 MAP kinases.[108]  Co-stimulation of human 
osteoblasts with TNF-α and IFN-γ resulted in downregulation of angiopoietin-1 expression, 
mediated in part through nitric oxide signaling.[131] 
1.2.3.3 Evidence For and Against Osteoclast-Stimulated Angiogenesis 
There are several papers reporting that angiogenesis is closely associated with OCL formation 
and activity, and that endothelial cells stimulate osteoclastogenesis.  Angiogenesis is closely 
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associated with increased OCL formation in multiple myeloma and other cancers, as well as 
inflammatory conditions such as rheumatoid arthritis.[2, 137]  Addition of bFGF or inhibition of 
NO production increases angiogenesis, OCL number and resorption on a bone chip implanted in 
the chick chorioallantoic membrane model.[138, 139]  Endothelial cells can stimulate OCL 
formation by several mechanisms including increased RANKL expression, and stimulate OCL 
formation in co-cultures by a RANKL dependent mechanism.[140]  Endothelial cells may also 
regulate the recruitment of OCL precursors to remodeling sites from the vascular compartment.  
Kindle et al showed that CD14+ cell adherence to and migration through endothelial cells, as 
well as subsequent OCL formation was increased by IL-1 and TNF-α.[141] 
Observations from patients with Gorham-Stout syndrome also support an association 
between osteoclastogenesis and angiogenesis.  Gorham-Stout syndrome is characterized by 
massive osteolysis and blood and lymphatic vessel infiltration.  Its pathogenesis is very poorly 
understood, but osteoclasts are believed to play a role in the resorption based on reports of 
successes using bisphosphonates for treatment and the ability of serum from a Gorham-Stout 
patient to induce osteoclastogenesis.[142, 143]  Cells isolated from Gorham –Stout patients, that 
showed some characteristics of OCL precursors, stimulated angiogenesis in the mouse matrigel 
plug assay.[144]  These cells expressed TRAP and αvβ3 integrin and adhered to osteopontin.  
Their production of VEGF and IL-8 was upregulated by TNF-α.  However, they were incapable 
of forming mature OCLs when stimulated with M-CSF, RANKL, or TNF-α. 
One study of Paget’s disease of bone suggested that OCLs stimulate angiogenesis.  
Paget’s disease is characterized by large, hyper-multinucleated and highly activated OCLs and 
elevated but disorganized bone remodeling.  Vascularity of Paget’s disease lesions was reduced 
after clodronate treatment, which inhibited OCL formation and activity.[3]  Furthermore, Paget’s 
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disease is also associated with high output congestive heart failure, which is consistent with 
tremendously increased bone vascularity.[145]      
However, there are few papers directly studying whether OCLs can stimulate 
angiogenesis.  Most prominent of these is Tanaka et al.[5]  The authors reported that conditioned 
media from human OCL cultures stimulated angiogenesis in vitro and that co-culture of OCLs 
with myeloma cells produces more in vitro angiogenesis than either OCLs or myeloma cells 
alone.  Further, they reported that neutralizing antibodies to osteopontin abrogated the OCL 
derived angiogenic activity and neutralizing antibodies to VEGF abrogated the myeloma cell 
derived angiogenic activity.  In addition, co-cultures of OCL and myeloma cells stimulated 
HUVEC migration and survival, and that osteopontin and VEGF caused release of a soluble 
osteoclastogenic factor by HUVECs.  However, since the authors did not purify the OCLs in 
their cultures, a significant contribution from macrophages or T-cells cannot be ruled out.  
Secondly, the neutralizing antibody approach may over emphasize the importance of any one 
factor and identify required factors in the mix of pro and anti-angiogenic factors, rather than 
identify the one most important factor.  For example using the same angiogenesis assay and a 
neutralizing antibody approach, other authors have identified either angiopoietin-1 or 
osteopontin as the most important angiogenic factor secreted by myeloma cells.[146, 147]  In 
addition, endothelial cells express osteopontin and therefore neutralizing antibodies to 
osteopontin could act on endothelial cells directly.[122]  In parallel, with these studies, VEGF-C 
expressed by osteoclast precursors stimulated lymphangiogenesis in an mouse arthritis 
model.[148]    
In contrast to the report of Tanaka et al, there are two published papers that asked 
whether OCLs were required for angiogenesis and found that they were not.[4, 149]  Deckers et 
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al studied blood vessel invasion into caudal vertebrae of neonatal mice in which OCL formation 
or activity was abolished by treatment with the bisphosphonate clodronate or using osteopetrotic 
mice (op/op or c-fos-/-) that lacked OCLs.  Blood vessels were able to invade the vertebrae under 
all three osteoclast-free conditions.  Similarly, in another study in osteopetrotic mice, vessels 
were able to invade the (non-mineralized) epiphyses of mouse tibiae.[149]  The results of these 
two papers are not definitive because the data were not quantitative, so small differences may 
have been missed.  In addition, different bone anatomic locations may respond differently to 
OCL pro-angiogenic effects.  As discussed in more depth below, in the paper characterizing the 
knockout mouse for the highly expressed OCL proteinase MMP-9, ossification and angiogenesis 
were delayed in growth plates of long bones.  Importantly, there was no defect in epiphyses or 
bones formed by  intramembraneous ossification.[14]  These authors also reported (data not 
shown) that there was delayed vessel invasion into the long bones from op/op and c-fos-/- 
osteopetrotic mice.  The results of 3 key papers addressing whether OCLs play a role in 
angiogenesis are summarized in Table 1.3.   
 
Table 1.3.  Key osteoclast and angiogenesis literature   
First Author Are OCLs angiogenic ??? Key Findings 
Tanaka[5] Yes OCL conditioned media stimulated 
angiogenesis in vitro due to osteopontin.  
Synergistic with myeloma cell-derived 
VEGF 
Deckers[4] No OCLs not required for vessel 
invasion of mouse tail vertebrae in vivo. 
Sugiura[149] No OCLs not required for vessel 
invasion of epiphyses in vivo. 
 
Several papers have analyzed OCL gene expression profiles using genomics and 
proteomics approaches and provided data supporting a role for OCLs in stimulating 
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angiogenesis.  Kiesel et al used microarrays to analyze gene expression of mouse bone marrow 
cultures at various timepoints of OCL differentiation induced with RANKL and M-CSF.[150]  
They made theoretical predictions as well as verified two processes experimentally.  They 
observed increased expression of angiogenic factors at 24 and 48 hours after induction of OCL 
differentiation, including members of the semaphorin family, VEGF-A and VEGF-C.  Like 
Tanaka et al, they showed that conditioned media from bone marrow cultures containing OCLs 
stimulated HUVEC tube formation on matrigel more than control media or conditioned media 
from cultures treated with M-CSF alone.   
However, other investigators using different cellular systems and genomic or proteomic 
techniques have not seen the same profile of angiogenic factors expressed by OCLs.  RANTES 
was increased in human peripheral blood derived OCLs at the mRNA level, and mouse marrow 
derived OCLs at the protein level.[151, 152]  TNF-α was likewise upregulated in human 
peripheral blood derived OCL and RAW264.7 (mouse cell line) derived OCLs both at the 
message level.[151, 153]  Other possible angiogenic factors were also upregulated during OCL 
differentiation including; urokinase plasminogen activator receptor [153], IGF-1 and PDGF-A 
[152], and osteopontin and MIP-1α..[154]  However, three other genomic or proteomic studies 
did not report upregulation of any angiogenic factors in OCLs.[155-157].  Therefore in several 
studies examining OCL gene expression with genomic and proteomic approaches, increased 
angiogenic factor gene expression during OCL differentiation has not been consistently detected.     
1.2.3.4 Bone Angiogenesis During Development 
The close spatial and temporal association between OCLs and capillaries in bone development 
and fracture healing suggests communication between OCLs and vessels, and OCL regulation of 
angiogenesis.  Physiologic bone angiogenesis occurs primarily during development and fracture 
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healing.  In endochondral ossification, cartilage is converted into bone and angiogenesis is 
required for the ossification process.[158]  In endochondral ossification, an avascular cartilage 
model (anlagen) of the final bone is first formed.  The chondrocytes then begin to hypertrophy 
and ossify in the two eventual centers of ossification; midshaft (primary) and epiphysis 
(secondary).  The marrow cavity is then formed by the concurrent invasion by osteoclasts (or 
chondroclasts) and blood vessels.[159]  This blood vessel invasion is essential for bone 
development and has been proposed to be the source of osteoblasts.[160]  Angiogenic factors are 
required for OCL entry into the anlagen.  A key finding for the mechanistic studies of this 
dissertation is;  MMP-9 was shown to be required for both blood vessel and OCL entry 
into the primary ossification center.[161]  Furthermore, the study reporting the phenotype of 
the MMP-9-/- mouse reported in their discussion section that osteopetrotic (op/op and c-fos-/-) 
mice had delayed developmental vessel invasion into the primary ossification center.[14]     
In agreement with the MMP-9 data, other investigators directly implicated VEGF or 
hypoxia pathways in bone development.  VEGF has been proposed to be the primary factor 
regulating this vessel ingrowth because systemic neutralization of VEGF inhibited vessel 
ingrowth into epiphyses in a mouse model.[162]  Hypoxia upregulates VEGF production by 
chondrocytes and requires HIF-1α for its effect.[163]   Osteoblasts have also been shown to be 
important in stimulating developmental bone angiogenesis.  The HIF pathway is important with 
contributions from both HIF-1α as well as other HIF-α forms.[15]  Angiogenic factors are also 
required for OCL entry into the anlagen.  Thus, bone development, angiogenesis and OCL 
invasion are closely linked. 
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1.2.3.5 Angiogenesis During Fracture Healing 
Fracture healing shares many features with developmental angiogenesis, so not surprisingly 
angiogenesis is also important to its progression.  A soft cartilaginous callus is first formed from 
a hematoma, a process analogous to the cartilage model of bone formed during development.  
The cartilage of the soft callus is then converted to woven bone primarily by way of 
endochondral ossification, where the cartilage hypertrophies and then is resorbed by OCLs.  
Finally, as in development, the woven bone is remodeled to its final form.[110]   
Because long bone fracture healing is analogous to development, it should not be 
surprising that the molecular regulation of the two processes is similar.  Notably, MMP-9 is also 
important for healing of long bone non-stabilized fractures, and this defect can be rescued by 
recombinant VEGF.[164]  As in the studies of MMP-9 in development, vessels and OCLs failed 
to or had delayed invasion of the hypertrophic cartiliage callus.  This led to enlarged calluses and 
non-unions.  However, it is unclear if the MMP-9 important for these observations was OCL 
derived because MMP-9 is also expressed by many macrophages and granulocytes in fractures.    
In agreement with the studies of MMP-9 in fracture healing, neutralization of VEGF inhibits 
fracture healing in mouse models.[165]   
Likewise, others have suggested that OCLs may stimulate angiogenesis in fracture 
healing due to heparanase mediated release of VEGF.  However, this study is purely 
descriptive.[1]  VEGF was previously known to bind heparan and be released by heparanase.  
These authors observed OCL expression of heparanase both during endochondral ossification 
and in formation of woven bone.  They also observed that OCLs were located between vessels 
and hypertrophic chondrocytes.  Thus, OCLs are in the correct anatomical position to stimulate 
angiogenesis.  However, no experiments were performed that showed OCL release of matrix 
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VEGF was important for angiogenesis, and no additional studies have been reported that support 
this hypothesis. 
In support of the hypothesis of this dissertation, lack of OCL or OCL inhibition with 
bisphosphonates impairs fracture healing.  RANK-/- mice have increased non-unions of non-
stabilized long bone fractures.  Even more importantly, they have reduced numbers of vessels in 
the fracture calluses.[166]  Likewise, OCL inhibition with bisphosphonates delays fracture 
healing.  Bisphosphonates were studied in a different fracture model than was used for RANK-/- 
or MMP-9-/- mice; stabilized rather than un-stabilized fractures.  Stabilized fracture models heal 
without a cartilage intermediate and are more analogous to membranous rather than 
endochondral ossification.  Perhaps due to this model difference, bisphosphonates did not cause 
non-unions, but delayed remodeling of the woven bone callus.[167, 168]     
In addition, in a study relevant to the work by Tanaka et al, osteopontin, which is 
expressed by OCLs and osteoblasts in bone calluses,[169, 170] has also been implicated in 
stimulating angiogenesis during fracture healing.  Studies in osteopontin-/- mice have shown that 
these mice had decreased early stage angiogenesis and bone strength in healing calluses.[171]   
1.2.4 Pathological Bone Angiogenesis 
1.2.4.1 Angiogenesis in Bone Metastases 
Angiogenesis has long been known to be important for formation of bone metastases in solid 
tumors.  More recently angiogenesis has also been shown to be important for hematological 
tumor growth, including myeloma bone lesions where bone angiogenesis is clinically important.   
Myeloma is a malignancy of plasma cells in which the malignant clone produces a 
monoclonal immunoglobulin and induces bone lesions.[172]  It is thought to develop from 
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MGUS (monoclonal gammopathy of uncertain significance), a condition requiring no treatment 
in which a monoclonal immunoglobulin is detectable but the patients have no end organ damage. 
[172]  The switch from a non-angiogenic to a pro-angiogenic phenotype in the bone marrow is 
thought to be important in the transition from MGUS to multiple myeloma.[173]  Regulation of 
angiogenesis in myeloma results from signals from the myeloma cells superimposed on the 
normal angiogenesis regulatory mechanisms.  Investigators have proposed paracrine loops 
between myeloma cells and bone marrow stromal cells to explain the enhanced angiogenesis in 
myeloma.[2]  VEGF, bFGF and TGF-β derived from myeloma cells upregulate bone marrow 
stromal cell production of IL-6.[174-176]    Adhesion of myeloma and bone marrow stromal 
cells likewise upregulated stromal cell IL-6.[176]  IL-6 then increases production of VEGF by 
myeloma cells thus forming a loop.[174]   
VEGF is a key angiogenic factor in myeloma in vivo, as illustrated by the ability of a 
VEGF inhibitor to block myeloma growth and angiogenesis and increase survival in a mouse 
model of myeloma.[177]  However, the mechanisms responsible for the transition from a non-
angiogenic phenotype in MGUS to a pro-angiogenic phenotype in myeloma are less clear.  
Asosingh et al reported that a switch from CD45+ myeloma cells, which do not express VEGF, to 
CD45- myeloma cells, which do express VEGF, correlated with the angiogenic switch in a 
mouse model of myeloma.[178]  Lack of CD45 expression was also correlated with progression 
from MGUS to myeloma and increased angiogenesis.[179]  However, in another study the 
expression of VEGF, bFGF and their receptors did not differ between plasma cells from MGUS 
patients and myeloma patients, suggesting that other factors are responsible for the angiogenic 
switch.[180]  The same paper also found that plasma cells from MGUS patients contained an 
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angiogenesis inhibitory activity.[180]  A multitude of other factors have been proposed to 
contribute to myeloma angiogenesis including angiopoietin-1 and osteopontin.[146, 147]     
1.2.4.2 Antiangiogenic Effects of Bisphosphonates 
:  An understanding of angiogenesis in bone metastases requires an understanding of the 
drugs most commonly used to treat them, nitrogen containing bisphosphonates (N-BPs), which 
have anti-tumor and anti-angiogenic effects.  These drugs reduce the incidence and severity of 
skeletal complications, relieve metastatic bone pain, and improve patients’ quality of life.[181]  
N-BPs are also effective in myeloma bone disease.[182]  A major effect of N-BPs is to inhibit 
bone resorption through effects on the OCL.  In vitro studies have suggested many possible 
mechanisms for the anti-resorptive effects of N-BPs, but the bulk of evidence is pointing towards 
disruption of the OCL cytoskeleton due to inhibition of farnesyl diphosphate synthase and 
resulting effects on prenylation of small GTPases in OCLs as the primary mechanism for the 
effects of N-BPs in vivo.[183, 184]  Note, as discussed earlier, GTPases are involved in M-CSF 
and integrin induced OCL cytoskeletal organization.[50]  The N-BPs alendronate and risedronate 
inhibited OCL resorption at ten fold lower concentrations than were required to induce apoptosis.  
Further, apoptosis inhibitors failed to inhibit resorption, thus arguing against a role for OCL 
apoptosis in N-BP inhibition of resorption.[185] 
Due to the core structure of N-BPs, which is analogous to pyrophosphate, they are 
deposited in bone matrix, where they are released as the osteoclast resorbs bone and secretes 
acid.  Thus, OCLs are likely exposed to higher concentrations of bisphosphonates in vivo than 
other cell types.  Therefore, the cell specificity of bisphosphonates may be determined more by 
pharmacokinetics than by their molecular target.  It has been estimated that OCLs are exposed to 
N-BP concentrations between 0.1 and 1 mM when resorbing bone.[186]  Treatment of rabbits 
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with the N-BP risedronate inhibited the prenylation of Rab proteins in OCLs but not in other 
bone marrow cells, thus supporting the OCL as the target of N-BPs.[187]  In a study using 
fluorescently labeled N-BPs in vivo, uptake was observed primarily in OCLs, with some uptake 
in a subpopulation of bone marrow cells and osteocytes.[188]  Alternatively, cell culture 
experiments have suggested that cells close in proximity to OCLs can be exposed to high 
concentrations of N-BPs through transcytosis from OCLs.[189]  
Bisphosphonates also have anti-tumor and anti-angiogenic effects.  The mechanisms of 
these effects are under investigation.  The N-BP zoledronic acid reduced angiogenesis and tumor 
burden in the 5T2 mouse myeloma model.[190]  Zoledronate, alendronate and neridronate 
inhibited angiogenesis in vitro at concentrations ranging from 10 to 50 μM.[191-193]  These 
concentrations are higher than the maximum serum zoledronic acid level achieved after infusion, 
so it unclear if a direct effect of zoledronate on endothelial cells can explain the anti-angiogenic 
effects of zoledronic acid.[194]  There is one report of bisphosphonates inhibiting angiogenesis 
in vivo in a non-neoplastic situation outside of bone tissue – testosterone stimulated 
revascularization of the rat prostate after castration.[3]  Bisphosphonates were shown to 
transiently accumulate in the prostate, so as with bone, their tissue specificity is likely regulated 
by pharmacokinetics.      
N-BPs have been associated with a complication called osteonecrosis of the jaw (ONJ) 
with a reported cumulative incidence for cancer patients treated with intravenous N-BPs ranging 
between 1 and 11%.[195]  The incidence in osteoporosis patients treated with bisphosphonates is 
many orders of magnitude lower.  In ONJ, a section of the maxilla or mandible necroses and 
becomes exposed to the oral cavity.  ONJ is painful and interferes with functioning.  It is usually 
self-limited but can be have a prolonged course in a minority of patients.  The mechanism by 
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which bisphosphonates may cause ONJ is unknown.  A recent report from a phase III trial of the 
RANKL monoclonal antibody (denosumab) found a comparable number of cases of ONJ in 
patients treated with zoledronate and denosumab (Amgen website, August 3, 2009).  This 
suggests that OCL inhibition in general, rather than specific properties of bisphosphonates, may 
cause ONJ.  Bisphosphonate suppression of bone remodeling is one of the most popular 
hypotheses for ONJ pathogenesis.[196]  Decreased angiogenesis due to bisphonates may also 
play a role in ONJ.  Recently, ONJ was reported in patients treated with the anti-VEGF antibody 
bevacizumab.[197]  Furthermore, a small retrospective study found more cases of ONJ in cancer 
patients treated with bisphosphonates and bevacizumab than bisphosphonates alone.[198].  ONJ 
is also linked to dental extraction or other dental surgery, and is associated with actinomyces 
infection.  Because of their ability to inhibit remodeling of the callus of fixed fractures in long 
bones, bisphosphonates may also contribute to ONJ due to affects on bone healing after dental 
trauma, such as extraction.[167, 168]  The conclusions of this dissertation offer potential insight 
into the pathogenesis of ONJ.       
1.3 POTENTIAL MOLECULAR MECHANISMS OF OSTEOCLAST –
STIMULATED ANGIOGENESIS 
Macrophages, which share a close lineage relationship with osteoclasts, are well established as 
pro-angiogenic cells.  Angiogenic factors produced by macrophages the regulation of their 
production provide a template for studies of the potential mechanisms utilized by OCLs to 
induce angiogenesis.  In addition, production of several angiogenic factors has been previously 
reported in osteoclasts.[6] 
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1.3.1 Macrophages and Angiogenesis 
1.3.1.1 Macrophage Angiogenic Factors 
Macrophages express a wide array of angiogenic factors including ;VEGF, FGF-1, FGF-
2, PDGF, TNF-α, angiopoietin 1, leptin, IL-6 and IL-8 .[199] [200]  Human peripheral blood 
macrophages promoted endothelial cell proliferation through FGF-1, FGF-2 and PDGF.[7]  
VEGF was the primary angiogenic factor produced by hypoxic mouse peritoneal macrophages 
and RAW 264.7 cells in the mouse corneal angiogenesis assay.[8]  Neutralizing antibodies to 
TNF-α inhibited mouse peritoneal macrophage induced angiogenesis in the chick chorioallantoic 
membrane, rat cornea and BCE capillary tube formation assays.[9]  Furthermore, treatment of 
human peripheral blood macrophage conditioned media with antibodies to IL-8 or TNF-α or IL-8 
antisense equally reduced rat corneal angiogenesis.[201]  Because several different factors are 
required for macrophage stimulated angiogenesis, it is not improbable that several different 
osteoclast derived factors acting directly on endothelial cells will be required for OCLs to 
stimulate angiogenesis.  Further the angiogenic phenotype of macrophages is greatly affected by 
their microenvironment.  For example, conditioned media from activated macrophages 
stimulates angiogenesis, whereas conditioned media from resting macrophages inhibits 
endothelial cell proliferation.[202]  Therefore, it will be important to determine the role 
activation of OCLs plays in OCL-stimulated angiogenesis.   
In addition to these direct mechanisms, macrophages may stimulate angiogenesis 
indirectly; by inducing angiogenic factor secretion by another cell type or by activating a latent 
angiogenic factor.  As an example of such an indirect mechanism, MMP-9 produced by 
macrophages was shown to be important for cervical cancer angiogenesis. The authors 
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hypothesized that MMP-9 exerted its pro-angiogenic effect through release of matrix bound 
VEGF and the resultant increased VEGFR2 binding.[13]   
1.3.1.2 Tumor Associated Macrophages 
Although macrophages might be expected to help the host eradicate tumors, the opposite 
occurs in most cases.[203]  In greater than 80% of clinical studies, increased tumor associated 
macrophage (TAM) density is associated with a poor prognosis. In contrast, less than 10% of 
studies show association of TAMs with an improved prognosis.[204]  It has been proposed that 
TH2 type or anti-inflammatory cytokines such as IL-4, IL-10, TGF-β and IL-13 in the tumor 
microenvironment induce macrophages into an alternatively activated state, termed M2 
macrophages, which lack anti-tumor activity.[205, 206]  One of the major ways in which 
macrophages can stimulate tumor growth is through their angiogenic stimulatory capacity.  For 
example, macrophages were associated with increased microvessel density in human breast 
tumor samples, and their production of MMP-9 was required for angiogenesis in a mouse 
cervical cancer model.[13]   
Even though TAM’s are a good illustration of the angiogenic potential of cells of the 
monocytic lineage (such as osteoclasts), it seems unlikely that angiogenesis induced by TAM’s 
and osteoclasts will be regulated by identical mechanisms.  For example, IL-4, IL-10 and IL-13, 
which play a role in the induction of the tumor enhancing phenotype of tumor associated 
macrophages, inhibit osteoclast formation in most experimental systems.[47, 48]  However, an 
examination of how inflammatory cytokines and ischemic condtions, which do not inhibit 
osteoclast formation, and also regulate macrophage angiogenic factor production, should be 
useful in predicting ways that osteoclast-induced angiogenesis may be regulated. 
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1.3.1.3 Regulation of Macrophage Stimulated Angiogenesis By Ischemia   
It has been over 25 years since macrophages were first shown to secrete soluble angiogenic 
factors in response to hypoxia.[207]  Since then, there has been a flurry of activity investigating 
which angiogenic factors are induced by hypoxia in macrophages and the signaling mechanisms 
that control their production.  Early on, lactate, which is associated with ischemic conditions due 
to anaerobic metabolism, was shown to increase the angiogenic stimulatory capacity of 
macrophages.[208]  Macrophages accumulate in diseased tissues in poorly vascularized sites, 
thus illustrating their role in the response to ischemia.[199]  Principle among the transcription 
factors shown to play a role in macrophage production of angiogenic factors is the HIF family of 
transcription factors.[209]  Most data suggest that HIF-2α is more important than HIF-1α for the 
induction of angiogenic genes in macrophages exposed to hypoxia.  Hypoxia induced HIF-2α 
protein to a much greater extent than HIF-1α protein in human monocyte derived 
macrophages.[210]  Using an angiogenic factor cDNA array, White et al showed that 
overexpression of HIF-2α was much more effective than HIF-1α overexpression at increasing the 
transcription of pro-angiogenic genes in response to hypoxia.[200] 
1.3.1.4 Regulation of Macrophage-Stimulated Angiogenesis by Inflammatory Cytokines 
and Bacterial Products   
Macrophages are unlikely to be exposed to ischemia in the absence of biological factors.  In 
addition to the effects of anti-inflammatory cytokines on tumor associated macrophages, 
inflammatory cytokines have also been shown to upregulate production of macrophage 
angiogenic factors.  IFN-γ and LPS, well known macrophage activators, can induce angiogenic 
factor production in macrophages and increase their production of angiogenic factors in response 
to hypoxia.[199]  The expression of some angiogenic factors stimulated by LPS involves platelet 
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activating factor (PAF) induction of NF-κB.  PAF inhibitors and p65 (NF-κB subunit) antisense 
block NF-κB DNA binding, angiogenic factor production, and mouse matrigel plug angiogenesis 
induced by mouse peritoneal macrophages treated with LPS.  Likewise in human monocytes, 
PAF antagonists or NF-κB inhibitors reduced LPS-stimulated endothelial cell sprout formation 
from microcarrier beads as well as monocyte production of VEGF, bFGF, TNF-α, IL-1α and IL-
8.[211]  LPS also stimulated VEGF release from murine macrophages by signaling through 
TLR4 and synergergizes with adenosing receptor A2A.[212]  TLRs 2, 7 and 9 also synergize with 
adenosine A2A receptors.[213]  M-CSF likewise stimulates secretion of VEGF in monocyte-
derived macrophages, possibly through HIF-1α, as HIF-1α protein and DNA binding is increased 
by M-CSF treatment.[214]  TGF-β, although usually classified as an anti-inflammatory cytokine, 
has also been shown to induce macrophage angiogenic factor production.  TGF- β1 was required 
for head and neck cancer cell induction of VEGF and IL-8 in macrophages.[215]  
Overexpression of smad 3/4 or HIF-1α increased the induction of VEGF in mouse 
macrophages.[216]   
1.3.2 Possible Osteoclast-Derived Angiogenic Factors 
1.3.2.1 Osteopontin 
Osteopontin (OPN) is released by myeloma cells [147] and osteoclasts [5] and was 
proposed to mediate OCL-stimulated angiogenesis.  Experiments with OPN-/- mice demonstrated 
reduced angiogenesis in fracture healing experiments as well as reduced angiogenesis and 
osteoclastogenesis when bone chips were implanted subcutaneously in mice.[171, 217]  OPN is 
expressed by OCLs, osteoblasts and endothelial cells and is a very abundant protein in bone that 
comprises 2% of the non-collagenous protein.[122, 218]   
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Osteopontin was proposed to stimulate angiogenesis by signaling through integrins on 
endothelial cells, principally αvβ3.  Osteopontin prevents endothelial cell apoptosis through 
binding to αvβ3 and inducing NF-κB activation through a pathway that requires ras and src 
.[219]  Osteopontin’s prevention of endothelial cell apoptosis was further shown to involve 
stimulation of osteoprotegrin expression, which prevents TRAIL mediated endothelial cell 
apoptosis.[220]  Osteopontin also stimulates adhesion and migration of endothelial cells.[221, 
222]  Osteopontin and VEGF cooperatively stimulate endothelial cell migration.  Pretreatment of 
endothelial cells with VEGF increases cell migration in response to osteopontin and induces 
endothelial cell expression of osteopontin and αvβ3.  VEGF also increases thrombin cleavage of 
osteopontin in vivo.  Thrombin cleaved osteopontin stimulates endothelial cell migration better 
than full length osteopontin in vitro.[222]  Osteopontin also has effects on OCLs and other cell 
types.   
Osteopontin-/- mice were originally reported to have no changes in bone density, but to 
have increased OCL formation in vitro.[223]  However, later studies have found a subtle increase 
in bone mass and increased OCL numbers in vivo as well as decreased OCL motility and 
resorption in vitro.[224]  Thus, OPN seems to be required for the function of OCLs rather than 
their formation.  This reduced functionality of OPN-/- OCLs was recently illustrated by the 
reduced size of their resorption space.[225]  In addition to reducing the functionality of OCLs, 
OPN is required for the induction of bone loss in some pathological conditions.  Osteopontin-/-
mice lose less bone mass relative to controls with ovariectomy or PTH treatment.[226, 227]  
Furthermore, the increase in OCL number in response to PTH was blunted in OPN-/- mice.  
Implantation of breast cancer cells induced more bone loss in OPN-/- mice compared to wt, 
showing that OPN is not required for increased bone loss in all circumstances.[228]   
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1.3.2.2 IL-8 and Other CXC Chemokines 
Different members of the CXC chemokine family can either stimulate or inhibit 
angiogenesis.  CXC chemokines that have the sequence; glutamate, leucine, arginine 
immediately N-terminal to the first cysteine residue (ELR+) are pro-angiogenic.[229]  The pro-
angiogenic effects of ELR+ CXC chemokines are thought to be due to signaling through 
CXCR2.[230]  CXC chemokines that lack the ELR motif are anti-angiogenic, and exert these 
effects primarily through isoforms of CXCR3.[231-234]  ELR+ CXC chemokines are secreted by 
several different cell types in bone marrow.  Osteoclasts were reported to produce IL-8, but not 
ENA-78 (CXCL5), GRO-α (CXCL1), GRO-β (CXCL2), GRO-γ (CXCL3) PBP, CTAP-III, β-
TG or NAP-2 (CXCL7).[121]  In addition to CXCR2, IL-8 also stimulates angiogenesis through 
CXCR1.  The relative contribution of CXCR1 and CXCR2 to IL-8 induced angiogenesis varies 
depending on the experimental system used, although it has been hypothesized that CXCR2 is 
more important.[235]  CXCR2 blockade abolished angiogenesis induced by pancreatic cancer 
cells.[236]  Blockade of CXCR1 or CXCR2 alone inhibited migration of human glioblastoma 
endothelial cells, and the combination almost completely inhibited their migration, which was 
due to autocrine IL-8.[237]  IL-8 stimulates angiogenesis through stimulation of endothelial cell 
proliferation, apoptosis and production of MMPs.[238]  These effects can also be mediated 
through endothelial cell autocrine IL-8.[239]   
Like osteopontin, IL-8 production is increased by inflammatory mediators including IL-1, 
IL-6, TNF-α, and LPS, as well as reactive oxygen species and hypoxia.[235, 240, 241]  IL-8 
expression is regulated both transcriptionally and at the level of mRNA stability by pathways 
involving JNK, IKK and p38 kinases.  The IL-8 promoter has at least 3 transcription factor 
binding sites; AP-1, NF-κB, and C-EBP/NF-IL-6.[235]  Initial studies on hypoxic regulation of 
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IL-8 expression did not detect a hypoxia –responsive element in the IL-8 promoter and found 
that IL-8 hypoxic upregulation was primarily due to AP-1.[241]  More recently, studies have 
shown that the IL-8 promoter does contain a site that can serve as a hypoxia-responsive element 
and that HIF-1α contributes to IL-8 regulation.[242]  IL-8 promotes OCL formation both by 
direct effects on the OCL and through upregulation of RANKL in stromal cells.[243, 244]    
1.3.2.3 MMP-9 
OCLs may also stimulate angiogenesis by release of proteinases, which can stimulated 
angiogenesis in many ways including; basement membrane degradation, less pericyte 
attachement, increased integrin signaling, or release of angiogenic stimulators (or inhibitors) 
from matrix.[245]  Such an enzymatic mechanism for osteoclast-stimulated angiogenesis may be 
more feasible than osteoclast-secreted angiogenic factors acting directly on endothelial cells, 
because OCLs are rare cells in bone.  Thus, proteinases could multiply the pro-angiogenic effects 
of OCLs.  An obvious candidate for this mechanism of action is MMP-9.  A possible role for 
OCL-derived MMP-9 in angiogenesis in development or fracture healing was briefly described 
earlier.  MMP-9 is a matrix proteinase, classically known to degrade denatured collagen 
(gelatin), but which also has other substrate specificities.[245]  Early studies showed that 
osteoclasts express high levels of MMP-9.  It was originally thought that MMP-9 was 
specifically expressed by osteoclasts or committed osteoclast precursors in bone.[246, 247]  
However, MMP-9 can also be expressed by other cell types such as hypertrophic chrondrocytes 
or osteoblasts during development, or macrophages and neutrophils expecially during fracture 
healing.[164, 248, 249]   
Observations of MMP-9-/- mice suggested that osteoclasts may play a role in 
angiogenesis.[14]  Yet, this possibility has remained unexplored.  MMP-9-/- mice are viable but 
 40 
show a bone phenotype consisting of delayed endochondral ossification and delayed blood vessel 
invasion into the metaphyseal growth plate center.  In this same report, the authors reported that 
op/op and c-fos-/- osteopetrotic mice showed a milder growth plate defect than the MMP-9-/- mice 
but did not show the data.  The initial study of the MMP-9-/- mouse found a similar pattern of 
expression of MMP-9 and the OCL marker TRAP in growth plates, but some cells at the 
chondro-osseous expressed MMP-9 but not TRAP or the endothelial cell marker CD31.[14]  A 
later study failed to show a defect in endochondral ossification in the same osteopetrotic (c-fos-/- 
and op/op) mice as well as in clodronate treated mice.[4]  However, this report examined mouse 
tail vertebrae, rather than the growth plate of long bones that were examined in studies of MMP-
9-/- mice.  Differences in the relative importance of the OCL to angiogenesis at various 
angiogenic sites may exist.  In agreement with this, the MMP-9-/- mouse has no ossification or 
vessel invasion defect in the epiphyses of long bones.   
Several investigations have reported that MMP-9 stimulates angiogenesis through 
activation or release of growth factors.  MMP-9 was first implicated as the angiogenic switch in 
a mouse pancreatic cancer model in which MMP-9 released matrix (heparan) associated VEGF 
and increased VEGF receptor occupancy.  The MMP-9 expressing cells in this study were not 
tumor cells but rather appeared to be infiltrating immune cells.[12]  Likewise, infiltrating 
zoledronate-sensitive macrophages were implicated in cervical cancer angiogenesis by way of 
VEGF release.[13]  MMP-9 release of matrix bound VEGF was suggested to be important for 
angiogenesis in the long bone growth plate.[161]  MMP-9 can also to act upon other pro and 
anti-angiogenic factors.  MMP-9 increases the activity of the pro-angiogenic molecule IL-8 on 
neutrophil activation, although angiogenesis was not examined.[250]  Furthermore, the pro-
angiogenic molecule GRO-α as well as the angiogenesis inhibitor PF-4 were degraded and 
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inactivated by MMP-9.[250]  In addition, MMP-9 activates TGF-β, which stimulates 
angiogenesis under most circumstances.[251, 252]  Osteoclasts have long been hypothesized to 
release TGF- β from bone matrix.  MMP-9 and MMP-2 can activate TGF- β through cleavage of 
latent TGF- β binding protein – 1.[11]  Thus, OCL-derived MMP-9 may increase the activity of 
TGF-β released from bone matrix by OCLs.    
MMP-9 affects OCL migration, which may be important for their ability to stimulate 
angiogenesis.  As discussed earlier, MMP-9 release of matrix bound VEGF is important for OCL 
and vessel invasion into the primary ossification center.[161]  In this study, resorption of E17 
metatarsal explants but not more mature bones was inhibited by lack of MMP-9.  This result was 
explanined by the MMP-9-/- migratory defect rather than by an effect on solubilization of 
calcified matrix.  At this stage, OCLs must invade from the periosteum in order to resorb 
calcified matrix.  In agreement with these data, an in vitro study found that lack of MMP-9 
inhibited OCL migration trough matrigel to underlying bone slices, and resulted in reduced 
resorption of due to the migratory effects.[253]  Furthermore, MMP-9 is important for migration 
of macrophage cell lines capable of forming OCLs.[254, 255]  Because of this importance for 
migration, OCL-derived MMP-9 may stimulate angiogenesis indirectly, by increasing the 
number of OCL at the angiogenic site.  Therefore, osteoclast-derived MMP-9 may stimulate 
angiogenesis by at least three different mechanisms; activation of VEGF or TGF-β, or 
affecting OCL recruitment to the angiogenic site.   
1.3.2.4 Other Proteinases 
In addition to MMP-9, several families of proteinases; MMPs, ADAMs and serine 
proteinases are involved in angiogenesis, many of which are expressed by OCLs (Reviewed in 
[256]).  Many of the well studied angiogenic MMPs are expressed by OCLs, including MMP-9, 
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MMP-7, MMP-2 and MT1-MMP.[248, 257]  Of note, MT1-MMP (MMP-14)-/- mice have a 
similar, but more severe, phenotype than MMP-9-/- mice, including defective endochondral 
ossification and vessel invasion, and inhibition of both axial and craniofacial skeletal 
growth.[258]   A recent report showed that MMP-7 was predominantly expressed by OCLs and 
important for growth of breast cancer bone metastases.[257]  However, angiogenesis was not 
analyzed in this report. MMP-7 may stimulate angiogenesis by several possible mechanisms, 
including stimulating endothelial cell migration or releasing EGF or VEGF from matrix.[245, 
259, 260]  
The ADAM family of proteinases is similar in structure to the MMPs and also affect 
angiogenesis by similar general mechanisms.  Many ADAMs, including ADAMs 8, 9, 10, 15, 17 
and 28, are expressed by OCLs.[261]  ADAM-17 (TACE) is especially well studied in 
angiogenesis due to it’s ability to release membrane bound TNF-α.[256]  Of the serine 
proteinases, plasmin and its regulators u-PA, t-PA and PAIs are of primary importance to 
angiogenesis.  Plasmin is best known for fibrinolysis, but also affects angiogenesis by activating 
other proteinases.[256]  Activation of proteinases relevant to angiogenesis involves complex 
pathways with much cross talk between various kinds of proteinases.  A well known cascade of 
proteinase activation controls the activity of MT1-MMP (MMP-14), MMP-2, MMP-13 and 
MMP-9.  MT1-MMP is activated by the serine proteinases furin and PC6.[262]  It in turn 
activates pro-MMP-2 and pro-MMP-13.[263, 264]  MMP-2 activity can be inhibited by β1 and 
αvβ3 integrin ligation.[265]  Both MMP-2 and MMP-13 are capable of activating MMP-9.[266, 
267]    
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1.3.2.5 TGF-β 
A particularly well-studied molecule that may be released by OCLs from calcified bone 
matrix, resulting in angiogenesis stimulation, is TGF-β.  Bone matrix is a rich source of growth 
factors and contains factors such as PDGF, aFGF, bFGF and TGF-β.[268, 269]  TGF-β has 
received an enormous amount of attention in the past two decades, as the key component in the 
“vicious cycle” hypothesis in which metastatic tumor cells stimulate OCLs, that release TGF-β 
from bone matrix to further stimulate tumor growth.[109]  OCL-released TGF-β may act on 
vessels directly, primarily on pericytes and mural cells as described above.[96]  Alternatively, 
TGF-β may stimulate angiogenesis through induced angiogenic factor expression in other cells.  
TGF-β as well as bone morphogenetic proteins have been shown to induce VEGF expression in 
osteoblasts.[108, 111]  The role of osteoblastic VEGF in angiogenesis in bone is well 
demonstrated.[15]         
Although the concept of osteoclastic release of TGF-β from calcified matrix has become 
dogma in bone biology and inspired promising experimental treatment approaches, the 
biochemical evidence that TGF-β comes directly from calcified matrix is limited.[10, 11, 270]  
Regardless of the exact source, TGF- β is associated with increased osteoclastogenesis and has 
important roles for bone biology.[109] 
 
The literature review above provides the necessary background information and rationale 
for the following studies.  Although some have described situations where angiogenesis does not 
require OCLs, we have identified models where OCLs do play a role, and are the first to show 
that OCLs are important for angiogenesis in vivo.  We are confident that future studies will 
describe additional ways in which OCLs contribute to angiogenesis.  The data in this dissertation 
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firstly demonstrates that OCLs can play a role in angiogenesis and then show that MMP-9 affects 
OCL-stimulated angiogenesis primarily through allowing OCLs to migrate to the angiogenic site.  
These studies allowed us to develop the following model of OCL-stimulated angiogenesis 
angiogenesis (Figure 1.5). 
 
 
Figure 1.5.  Model of osteoclast-stimulated angiogenesis 
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2.0  OSTEOCLASTS CONTRIBUTE TO ANGIOGENESIS 
2.1 SUMMARY 
Osteoclastogenesis is correlated with angiogenesis in biological processes such as development, 
fracture healing and inflammatory and malignant bone diseases.  However it is unclear if OCLs 
play a causal role in angiogenesis.  Other investigators previous or concurrent with these studies 
reported conflicting data on a requirement for OCLs in angiogenesis.  To determine if OCLs are 
important for angiogenesis, we examined their contribution to the process in three model 
systems.  Firstly, we examined the ability of conditioned media from human bone marrow OCLs 
to stimulate angiogenesis in the HUVEC / fibroblast co-culture angiogenesis assay.  To 
determine if OCLs stimulated angiogenesis in a bone microenvironment in vitro, we employed 
the fetal mouse metatarsal angiogenesis assay.  This assay employs bone explants from fetal 
mice, which contain bone cell types including OCLs, osteoblasts, chondrocytes, fibroblasts and 
endothelial cells, to permit testing OCL modulators for their effects on angiogenesis.  We 
examined the effect on OCL-stimulated angiogenesis in vivo after 5 day RANKL or PTHrP (1-
34) treatment of mice by histological evaluation of fixed frozen sections stained for the OCL 
marker TRAP and immunohistochemical staining of vessels (CD31) in calvaria.  Human bone 
marrow OCL conditioned media stimulated in vitro angiogenesis at a comparable level to other 
bone marrow cell types known to stimulate angiogenesis.  OCL inhibition with osteoprotegerin 
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decreased angiogenesis and OCL formation and activity in parallel in metatarsal explants.  
Conversely, continuous PTHrP (1-34) increased both area covered by endothelial cells and 
osteoclastic resorption (CTX) in metatarsal explants.  This ability of PTHrP to stimulate 
metatarsal angiogenesis disappeared with osteoprotegerin treatment, and PTHrP did not induce 
angiogenesis in metatarsals from OCL deficient op/op mice, thus showing that the angiogenic 
effect of PTHrP requires OCLs.  Furthermore, in vivo studies demonstrated that OCL stimulation 
with 5 days of RANKL or PTHrP treatment increased vessel density in mouse calvaria.  Total 
CD31+ vessel area was dramatically increased between the bone tables in PTHrP compared to 
vehicle treated animals, with most of the effect due to vessel number.  RANKL increased vessel 
density and area in the outer table of calvaria in vivo.  Thus, by demonstrating OCL stimulation 
of angiogenesis in two in vitro models 
 
2.2 INTRODUCTION 
Both osteoclastogenesis and angiogenesis are enhanced in pathological conditions, such 
as multiple myeloma, bone metastases and rheumatoid arthritis, which are associated with locally 
increased inflammatory cytokines.[2, 137]  Osteoclasts (OCLs) and blood vessels are closely 
associated, with a vessel present at every bone remodeling compartment.[107]  However, few 
studies have examined if and how OCLs may play a role in angiogenesis.  OCL conditioned 
media has been reported to be angiogenic in vitro and this angiogenic activity was attributed to 
secretion of osteopontin by OCLs, which was increased when OCLs were co-cultured with 
multiple myeloma cells.[5, 150]  However, other investigators reported that OCLs were not 
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required for angiogenesis.  Further, osteopetrotic (lacking OCLs) genotypes (op/op or c-fos -/-) or 
clodronate treatment of wild type mice did not inhibit developmental vessel invasion into mouse 
caudal vertebrae.[4]  Likewise, op/op mice have normal levels of vessel invasion in their 
epiphyses.[149]  Therefore, we chose to investigate whether OCLs are important for 
angiogenesis    
2.3 MATERIALS AND METHODS 
Materials:  Monoclonal rat anti-mouse CD31 was purchased from BD-Pharmingen (#550274).  
Vector Laboratories supplied biotinylated rabbit anti-rat (mouse adsorbed) and SA-HRP.  The 
RatLaps C-terminal type I collagen telopeptide (CTX) assay was obtained from Nordic 
Biosciences / Immunodiagnostic Systems, and the CryoJane sectioning aid and adhesive slides 
from Instrumedics – Leica.  Human in vitro angiogenesis assays were purchased from TCS 
Cellworks.  rh OPG-Fc, rh RANKL and rh M-CSF were from R&D Systems.  Recombinant 
mouse RANKL-GST was generously provided by Dr. F. Patrick Ross (Washington Univ, St. 
Louis).  h PTHrP (1-34) was purchased from American Peptide.  The 23c6 monoclonal antibody, 
which identifies αvβ3 integrin, cell culture supernatant was provided by Dr. Michael Horton, 
University College, London, UK.  The BCA protein assay was from Pierce.  ImmunoHistoMount 
aqueous mounting media and other chemicals or supplies were purchased from Santa Cruz, 
Sigma-Aldrich, Fisher Scientific, Electron Microscopy Sciences or Gibco.  C57BL/6 mice were 
from Harlan.  
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Human OCL culture and analysis of angiogenic activity of conditioned media in 
vitro:  After obtaining informed consent, bone marrow aspirates were collected in heparinized 
syringes from normal donors.  These studies were approved by the University of Pittsburgh 
Institutional Review Board.  Marrow mononuclear cells were separated by density sedimentation 
on ficoll-hypaque.  107 cells were incubated overnight in 10% FCS αMEM in 10 cm culture 
dishes.  Non-adherent cells were removed by gentle washing.  Adherent cells were cultured in 
Dexter-type cultures for 21 days in 10% FCS IMDM with twice weekly media changes to obtain 
marrow stromal cells.[272]  For osteoclast or macrophage culture, non-adherent cells were 
diluted to 106 / mL in α-MEM with 20% horse serum, 10 ng/mL rh M-CSF with or without 50 
ng/mL rh RANKL and seeded at 30 mL per T-75 flask.  Cultures were maintained for 3 weeks 
with twice weekly changes of half the media volume containing a full complement of cytokines, 
as previously described.[19]  Osteoclast cultures were trypsinized for 5 minutes at 37°C to 
remove contaminating cell types, then rested for 24 hours, followed by RNA or conditioned 
media collection.  Serum free conditioned media was collected by washing the cultures three 
times with α-MEM, adding back 7.5 mL of α-MEM per flask and then incubating the cells for 24 
hours at 37oC.  Cultures were fixed and stained for αvβ3 integrin with the 23c6 monoclonal 
antibody that identifies OCLs and Vector ABC-AP kit.  Conditioned media or control media was 
concentrated 10 fold on Amicon 3 KD cut-off concentration columns that were pre-blocked with 
1% BSA, then diluted back so that at final concentration CM from 30,000 OCLs per ml was 
added to the TCS Cellworks in vitro angiogenesis assay.  Co-cultures of human umbilical vein 
endothelial cells (HUVECs) and fibroblasts was performed per manufacturer’s protocol.[273]  
CM was diluted 1:2 to provided assay media.  After 11 days, cultures were stained for CD31.  
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Cultures were photographed with an Olympus multimode dissecting microscope and quantified 
for total CD31+ area with ImageJ and for angiogenic tube formation with Metamorph software.         
 
Fetal Mouse Metatarsal Angiogenesis Assay:  The assay was conducted as originally 
described with minor modifications.[17]  Briefly, embryos were harvested from CB6 F1 x CD-1 
(outbred), C57BL/6 WT or C57BL/6 MMP-9-/- pregnant female mice that were sacrificed with 
an excess of isofluorane anesthesia at 17.5 dpc.  The middle three metatarsals were dissected 
from each hind leg and cultured in 24 well plates containing 10% fetal calf serum α–mimimal 
essential media with the indicated treatments for 15 days.  At least 10 bones were used per 
group.  Media volume was maintained at 150 μl for the first three days and 250 μl subsequently. 
Media was replaced every three days and spent media was stored at -80oC for measurement of 
CTX (RatLapsTM, Nordic Biosciences).  Media from freeze-thawed bones was used as a blank 
for CTX measurements.  Explants were then stained for CD31 as follows:  Bones were fixed for 
15 minutes with zinc macrodex formalin, washed twice with PBS and blocked overnight at 4oC 
in PBS containing 2% rabbit serum, 0.1% triton X-100, 0.05% tween-20, 1% BSA, 0.1% gelatin 
and 0.05% sodium azide.  All PBS buffers were at pH 7.2.  The primary antibody was applied at 
a dilution of 1:50 in PBS plus 1% BSA and 0.1% gelatin.  Secondary antibody and SA-HRP 
(Vector Laboratories) were applied in PBS at 1:100 or 1:250 dilution respectively, and explants 
were stained with AEC-HRP substrate.  Images were acquired with an Olympus Multimode 
dissecting microscope and were quantified either with the MetamorphTM angiogenesis tube 
formation application for tube area, length and branches, or with ImageJ for total CD31+ area 
and corrected for the area of bones stained with control IgG in place of primary antibody.     
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TRAP activity was extracted from metatarsal explants that were fixed and stained for 
CD31 and stored dry.  Bones were rehydrated in water, removed and homogenized with a 2 mL 
ground glass homogenizer in 120 μl NP-40 lysis buffer (1% NP-40, 150 mM NaCl, 50 mM tris 
pH 8), then rotated at 4oC overnight and cleared by centrifugation.  To assay TRAP activity, 35 
μl of homogenate was added to 200 μl TRAP substrate (50 mM sodium acetate pH 5, 25 mM 
sodium tartrate, 0.4 mM MnCl2, 0.4% N,N,-dimethylformamide, 0.2 mg/mL fast red violet, 0.5 
mg/mL napthol AS-MX phosphate), then incubated 3 hours at 37oC and the absorbance read at 
540 nm.  Results were corrected for total protein, which was assayed by adding 25 μl 
homogenate to 250 μl BCA assay reagent, incubating 2 hrs at 37oC and reading the absorbance at 
562 nm.                   
 
Histology and Immunohistochemistry:  Histological analyses were performed in fixed-
frozen decalcified tissues from mice.  Bones were fixed overnight in 2% paraformaldehyde, 
decalcified for 4 days in 10% EDTA pH 7.4, imbedded in 30% sucrose in PBS overnight and 
snap frozen in OCT by immersion in LN2 cooled isopentane.  Seven μm sections were cut on a 
cryostat equipped with a CryoJane tape-transfer system.  Slides were stored frozen until use, and 
then thawed and washed 3 times in PBS.  For immunohistochemistry, slides were peroxidase 
quenched in 0.3% H2O2 in MeOH, washed 3x for 5 minutes in PBST (0.05% Tween-20), then 
blocked for 30 minutes in 5% serum from the same species from which the secondary antibody 
was derived.  Primary antibodies were applied overnight at 4oC in PBS at the following dilutions; 
anti-CD31 (1:100), anti-MMP-9 (1:4000), followed by washes in PBST, and then biotinylated 
secondary antibodies (anti-rat 1:100, anti-rabbit 1:2500 dilutions), SA-HRP (1:250 dilution) and 
DAB peroxidase substrate were added.  TRAP histochemistry was performed with a substrate 
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solution containing 50 mM sodium acetate pH 5, 25 mM sodium tartrate, 0.4 mM MnCl2, 0.4% 
N,N,-dimethylformamide, 0.2 mg/mL fast red violet, 0.5 mg/mL napthol AS-BI phosphate as 
described previously.[274]  Slides were coverslipped in aqueous mounting media. 
 
In vivo studies:  Six (2 male and 4 female) C57BL/6 7 week old mice per group were 
injected with m-RANKL-GST (1 mg/kg in 50 - 65 μl PBS) subcutaneously over the calvaria 
daily for 5 days under light isoflurane anesthesia.  Similarly, for studies involving PTHrP, six 5 
week old male C57BL/6 were treated with 2 μg h PTHrP (1-34) in 100 μl 1% BSA-PBS pH 5.2 
systemically by subcutaneous injection 4 times a day for 5 days.[51, 275]  Control mice were 
injected with vehicle.  After 5 days, blood was collected by retro-orbital puncture and mice were 
sacrificed.  Calvaria were sectioned in a coronal orientation anterior to the junction of the sagittal 
and coronal sutures, and stained for CD31, TRAP or MMP-9.  All quantitative histological 
analyses were performed by a blinded observer.  For PTHrP treated mice, CD31+ vessels were 
quantified in the inner table adjacent to the midline of 10x objective images by selecting the 
DAB signal with a hue saturation intensity filter (Fovea Pro software, Reindeer Graphics) 
selected to limit to true signal from 45 to 90° area running within Adobe Photoshop 7.  For 
PTHrP treated mice between bone tables (parasagittal spaces), or RANKL treated mice in the 
outer table, CD31+ vessels were quantified by counting vessel numbers and using a grid map 
projected with ImagePro software to determine total area covered by vessels (including lumens).  
Average vessel size was calculated from total area and vessel density.  OCLs were quantified in 
PTHrP treated bones by calculating TRAP+ area as for DAB using Fovea Pro as above selecting 
between 45-89°.  OCLs were quantified in RANKL treated calvaria calculating the TRAP+ 
(resorptive) surface of the sub-periosteal surface of the calvarial outer table by grid map 
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counting, as well as TRAP+ area.  All animal protocols were approved by the IACUC of VA 
Pittsburgh Healthcare System, University of Pittsburgh, or Virginia Commonwealth University. 
 
Statistical Analyses:  The unpaired Student’s t-tests or one way ANOVA with LSD 
procedure were used for analyzing 2 or multiple groups respectively.  To analyze correlation, the 
Pearson correlation coefficient was calculated by linear regression, and the 1 sample F-test for a 
correlation coefficient was used to test for significance.  Two-tailed analyses were performed 
with SPSS software.  Significance was set at α = 0.05.      
2.4 RESULTS 
2.4.1 OCL Conditioned Media Stimulates Angiogenesis in vitro to a Similar Extent as 
Other Bone Marrow Angiogenic Cell Types 
We developed a model system where the angiogenic activity of OCL conditioned media (CM) 
could be assayed with co-cultures of HUVECs and fibroblasts.  Several initial dose finding 
studies determined that OCL CM had to be concentrated to observe an effect.  As shown in 
Figure 2.1 (A), the angiogenic effect of OCL CM was dose responsive but plateaued.  Based on 
these dose response studies, we concentrated CM adequately so that the media in the 
angiogenesis assay contained the secretions of 30,000 OCLs per ml.  Because of the need to 
concentrate conditioned media and because of interfering effects of serum used in OCL cultures, 
CM was collected under serum free conditions.   
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 To compare the angiogenic capacity of OCLs to other bone marrow cell types 
known to stimulate angiogenesis, we compared the activity of OCL, macrophage or bone 
marrow stromal cell conditioned media collected from equivalent numbers of cells.  The 
angiogenic capacity of OCLs was similar to these other cell types (Figure 2.1 B).  
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Figure 2.1.  Osteoclast conditioned media stimulates angiogenesis in vitro. 
(A)  OCL CM stimulates angiogenesis in the HUVEC / fibroblast co-culture angiogenesis assay.  Serum 
free conditioned media was collected from human BM OCL cultures and concentrated 5.6 fold, then diluted out to 
yield the working concentrations of products of indicated number of OCL / ml assay media.    (B)  OCL CM 
stimulates angiogenesis by comparable amounts to other angiogenic bone marrow cell types on a per-cell basis.  
Conditoned media was concentrated so that products of 30,000 OCL per ml and products of equivalent total cell 
numbers for each cell type were added to the HUVEC / fibroblast co-culture angiogenesis assay.      
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2.4.2 OCL inhibition decreases angiogenesis in metatarsal explants 
After having shown that OCL CM is angiogenic, we wanted to determine if OCLs can stimulate 
angiogenesis under more physiological circumstances.  To determine if OCLs also contribute to 
angiogenesis in a more physiologic model for bone than purified cell cultures, we determined the 
effects of modulating OCL number and activity on angiogenesis in the fetal mouse metatarsal 
assay.  In this assay, metatarsals from E17.5 mice are cultured in vitro in the presence or absence 
of cytokines or hormones.  At this developmental stage, the primary ossification center is formed 
but not yet invaded by OCL precursors, which are in the periosteum.  Endothelial cells form 
tubes in a mixed cellular outgrowth during culture.[17]  This assay has been used to analyze the 
effects of osteoblast specific gene knockouts on angiogenesis.[15]  As shown in Figure 2.2 A, 
inhibition of OCL formation with osteoprotegerin (OPG) reduced angiogenesis in a dose-
dependent manner, as measured by staining endothelial cells with CD31 and quantitative image 
analysis of angiogenic tube formation.  To verify that OPG inhibited OCL formation and 
activity, we measured type I collagen (bone collagen) C-terminal telopeptide (CTX) levels in the 
conditioned media (CM) or activity of TRAP (OCL marker) extracted from the bone explants 
treated with OPG (Figure 2.2 B).  There was a parallel decrease in angiogenesis, CTX 
concentration, and TRAP activity.  To verify that OPG was not toxic to endothelial cells, we 
treated the HUVEC / fibroblast co-culture angiogenesis assay, which does not contain OCLs, 
with equivalent doses of OPG and observed a slight increase in angiogenesis (2.2 D). rather than 
any decrease due to possible toxitity.  Direct stimulatory effects of OPG on endothelial cell have  
been previously observed.[135]  Therefore, the metatarsal studies may have slightly 
underestimated the importance for OCLs to angiogenesis. 
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Figure 2.2.  Osteoclast inhibition with osteoprotegerin decreases angiogenesis in fetal metatarsal 
explants.   
(A) Metatarsal explants stained for endothelial cells (Red, CD31).  17.5 ED outbred fetal mouse metatarsals 
were cultured with indicated treatments for 15 days before fixation:  (i) control, (ii) 333 ng/mL, (iii) 1 μg/mL, (iv) 3 
μ/mL rh OPG-Fc.  Arrow: area of osteoclastic resorption which is prominent in the control bones and decreases with 
increasing OPG. (B) Quantitation of angiogenic outgrowth and OCL number and activity in metatarsal explants.  (i) 
Number of branches and other angiogenesis tube formation parameters quantified at end of the assay period (15 
days).  (ii) CTX (RatLaps) assayed from metatarsal explant conditioned media collected from days 7 to 9 of culture.  
(iii) TRAP activity extracted by homogenization of bones after 15 days of culture and assayed by color development 
using a TRAP substrate.  Mean ± SEM.  *:  p < 0.05.  Images aquired as whole mounts in water with an Olympus 
IX71 microscope with a UPlanFLN objective, NA of 0.13 and a Spot RTKE camera with Spot Advanced software.  
Original magnification x 4.  (C) Correlation of OCL activity and angiogenesis.  The TRAP activity extracted from 
bone explants and angiogenesis (branch points) was correlated for all samples treated with varying concentrations of 
OPG-Fc, and analyzed by linear regression.  r: Pearson correlation coefficient, p: significance by 1 sample F-test for 
linear regression.  (D)  Lack of anti-angiogenic effect in the OCL free HUVEC / fibroblast co-culture angiogenesis 
assay.   The assay was treated with the indicated concentrations of rh OPG-Fc and quantified with Metamorph 
software for angiogenic tube formation.  Mean ± SEM.  *:  p < 0.05.    
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2.4.3 Osteoclast Stimulation Increases Angiogenesis in Metatarsal Explants 
Having shown that OCL inhibition in metatarsal explants decreased angiogenesis, we next 
investigated if angiogenesis was increased by OCL stimulation.  As shown in Figure 2.3 A, 
stimulation of OCL formation with PTHrP, which stimulates osteoclastogenesis primarily 
through increased RANKL expression on osteoblasts, increased the area of CD31+ endothelial 
cells in metatarsal explant cultures.  Because PTHrP can have direct effects on osteoblast 
differentiation or survival, we also treated the explants with OPG to determine if the angiogenic 
effect of PTHrP required OCLs.  PTHrP failed to stimulate angiogenesis in the presence of OPG 
(Figure 2.3 A (iv)).  OCL stimulation and inhibition did not simply have opposite effects on 
explant angiogenesis, but rather had differing effects on the morphology of the endothelial cell 
outgrowth.  As shown in figure 2.3 B (i), PTHrP increased CD31+ area 1.5 fold due to increased 
density of endothelial cells adjacent to the bone.  However, parameters of endothelial tube 
formation, such as number of branch points, which were inhibited by OPG, were not increased 
by PTHrP treatment (Figure 2.3 B (ii)).  The reasons for these contrasting effects on endothelial 
morphology are under investigation.     
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Figure 2.3.  Osteoclast stimulation increases angiogenesis in fetal metatarsal explants 
(A)  PTHrP stimulates angiogenic outgrowth from metatarsal explants by a mechanism requiring 
osteoclasts.  Whole mount fetal metatarsal explants from outbred mice cultured for 15 days with vehicles (i), 3 
μg/mL rh OPG-Fc (ii), 100 nM h PTHrP (1-34) (iii) or OPG + PTHrP (iv), fixed and stained for CD31 (Red).  
Images aquired as whole mounts in water with an Olympus IX71 microscope with a Plan N 2x objective, NA of 
0.06 and a Spot RTKE camera with Spot Advanced software.  Original magnification x 2.  (B)  Quantification of 
angiogenic response to PTHrP and OPG.  Angiogenesis was quantified by measurements of total CD31+ area (i) or 
angiogenic tube formation (branches) (ii).  Mean ± SEM.  *:  p < 0.05.  Similar results were seen in 2 experiments.  
Results represent one representative experiment of 2 performed. 
 
 
2.4.4 OCL Stimulation with PTHrP or RANKL Increases Angiogenesis in vivo in Mouse 
Calvaria   
We next determined if OCL stimulation increased angiogenesis in mice treated with PTHrP.  
Therefore, mice were treated with PTHrP every 6 hours subcutaneously for 5 days and then 
analyzed for OCLs and vessels histologically.  This protocol has been used previously to 
dramatically induce OCL formation in calvaria and by frequent dosing is designed to minimize 
possible osteoblastic (anabolic) effects of PTHrP.[275]  OCLs and blood vessels, labeled for the 
endothelial cell marker CD31, were dramatically increased between the bone tables in calvaria 
following PTHrP treatment (Figure 2.4A).  OCL stimulation with PTHrP was less dramatic in 
femorae.  The pattern of vessels in the metaphysis adjacent to the growth plate was changed, but 
there were no significant differences in vessel area (Figure 2.4B).  The dramatic increase in total 
CD31+ vessel area normalized to tissue area was primarily due to increased vessel number rather 
average size of each vessel (Figure 2.4C).  Average vessel size was not significantly increased 
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(data not shown).  Cells of the reticuloendothelial system, such as those found in sinusoids of the 
bone marrow or liver do not express CD31.[104]  Thus, these data reflect changes in endothelial 
cells of capillaries and arterioles rather than the venous sinusoids.  PTHrP treatment was also 
characterized by an anabolic response within the calvarial inner table and associated tissue, 
resembling the response seen in hyperparathyroidism termed “osteitis fibrosa cystica.”  The 
thickness of the inner table was increased 4 fold with PTHrP treatment (Figure 2.4D).  CD31+ 
vessels in the inner table increased in proportion with tissue area in PTHrP treated bones.  Thus 
CD31+ vessels in the inner table were not increased when normalized for tissue area (data not 
shown).  As an illustration of the osteoclastic response to PTHrP, OCLs, as measured by TRAP+ 
area within the whole section, were increased with PTHrP treatment (Figure 2.4E).  
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Figure 2.4.  PTHrP stimulates angiogenesis in vivo 
(A)  Stimulation of OCL activity by PTHrP increases angiogenesis in mouse calvaria in vivo.  Coronal 
sections of calvaria from mice treated with h PTHrP (1-34) every 6 hours for 5 days, labeled for CD31 (brown) and 
TRAP (red), and lightly counterstained with hematoxylin.  Prominent CD31+ vessels are indicated by arrows.  The 
inner table thickness is indicated by a 2 headed arrow.   (B) Effects of PTHrP on vessels at femoral growth plate.  
Images are oriented with the growth plate at the top and metaphysis at the bottom.  Sections are labeled for CD31 
(brown) and counterstained (methyl green)  (C)  PTHrP increases CD31+ vessel density between calvarial bone 
tables.  Total vessel area and vessel density quantified by grid map counting by a blinded observer of the para-
sagittal areas of CD31 stained calvarial sections.  (D)  PTHrP increases thickness of inner table. Total tissue area of 
the inner table was quantified by image analysis by a blinded observer.  (E)  PTHrP induces OCL formation in 
calvaria.  Total TRAP+ area as a percentage of tissue area was quantified by image analysis by a blinded observer.  
Mean ± SEM.  *:  p < 0.05 compared to vehicle.  Results represent one representative experiment of 2 performed.    
 
 
Because PTHrP can affect osteoblasts and other cells in addition to OCLs, we next 
studied the effect of RANKL on angiogenesis since RANKL does not affect osteoblasts, 
(reviewed in[63]).  We stimulated OCLs by supra-calvarial injection of RANKL to determine if 
OCL stimulation increased angiogenesis.  We observed dramatic bone resorption and OCL 
formation in the outer table with RANKL treatment (Figure 2.5 A).  The resorbed area was 
replaced by non-calcified tissue resembling osteitis fibrosa and containing dense vessel invasion.  
Both vessel area and vessel size were increased by OCL stimulation (Figure 2.5 B).  As 
expected, RANKL increased OCL formation as measured by TRAP+ area and resorptive surface 
(Figure 2.5 C). 
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Figure 2.5.  RANKL stimulates angiogenesis in vivo 
(A)  Supra-calvarial RANKL increases angiogenesis and OCL formation in calvaria of mice.  Images of the 
outer table of calvarial sections stained for TRAP (red) and CD31 (brown) and lightly counterstained with 
hematoxylin.  Arrow: CD31+ vessel in remodeling bone.  Green two headed arrow indicates the thickness of 
RANKL induced bone remodeling.  Outer surface is at the top of the image.  Auto contrast and auto color 
adjustment was performed with Adobe Photoshop software.  (B)  Quantification of RANKL induced vessel response 
by calculation of CD31+ vessel density or area in the outer table of 10x objective images taken at the calvarial 
midline.  (C)  Total percent TRAP+ area or the calvarial outer table or resorptive surface of the outer table sub-
periosteal surface.  Mean ± SEM.  *:  p < 0.05 
  
2.5 CONCLUSIONS 
In these studies we demonstrated that OCLs stimulated angiogenesis in vitro, in bone explants 
and in vivo in calvaria.  We showed that OCL conditioned media is angiogenic, and of 
comparable activity to other bone marrow cell types known to stimulate angiogenesis.  We show 
that stimulating or blocking OCL formation and activity in bone organ cultures results in parallel 
changes in angiogenesis, and stimulating osteoclastogenesis in vivo increases angiogenesis.  
Prior to our studies, the role of OCLs in angiogenesis was unclear.  Prior to, or concurrent with 
our studies, other groups have reported angiogenic activity of OCL CM but have not 
demonstrated an in vivo role of OCLs in angiogenesis.[5, 150]   
The limited literature looking at a possible role for OCL stimulated angiogenesis in vivo 
is contradictory.  Vu et al reported in their discussion section that osteopetrotic (c-fos -/- and 
op/op) mice have delayed blood vessel invasion into the primary ossification center and growth 
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plate in vivo.[14]   However, other investigators found that OCLs do not play a role in 
angiogenesis and reported that lack of OCLs did not affect blood vessel invasion into the 
epiphyses of tibiae or mouse tail vertebrae.[4, 149]  These results suggest that OCLs are likely to 
be less important for angiogenesis in vertebrae and long bone epiphyses.  Differences in the role 
of other bone cell types on angiogenesis at different bone anatomic sites have been reported, and 
thus the contribution of OCLs to angiogenesis may differ at different anatomic sites.  For 
example, osteoblast contributions to angiogenesis are more important in long bones than 
calvaria.[15]  
The studies in this chapter show an important role for the OCL in angiogenesis 
stimulation.  We showed that OCL conditioned media has angiogenic activity in vitro.  This data 
demonstrates that OCLs secrete a factor(s) which can act directly on endothelial cells.  The 
studies in this chapter do not show whether such a direct effect of OCLs on angiogenesis is their 
primary mechanism for angiogenesis stimulation in vivo.  More complex mechanisms may be at 
play.  OCL-stimulated angiogenesis may result from release of angiogenic factors from matrix.  
Alternatively, a linked osteoblastic response may also be required for OCL-stimulated 
angiogenesis.  In support of a coupled proliferative response of osteoblasts or other cells playing 
a role in OCL-stimulated angiogenesis, OCL stimulation by PTHrP or RANKL in vivo was 
indeed accompanied by osteoblastic and “osteitis fibrosa” responses.  Since osteoblast derived 
VEGF is clearly important for angiogenesis, osteoblasts and OCLs may cooperate to stimulate 
angiogenesis in bone.  
Because PTHrP can also induce proliferation of osteoblasts as well as OCLs, we can not 
rule out that osteoblastic effects of PTHrP may have contributed to its angiogenic effects in 
vivo.[63]  However, because RANKL, which has no osteoblastic effects, also simulated 
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angiogenesis, we are confident in reporting that OCLs stimulate angiogenesis in vivo.  We 
showed in the metatarsal system that any possible angiogenic effects of PTHrP due to its direct 
effects on osteoblasts require OCLs, because the angiogenic effects or PTHrP were blocked by 
the OCL inhibitor osteoprotegerin (OPG).  We attempted to perform the analogous experiment in 
vivo but were unable to obtain sufficient quantities of OPG that was active in mice.        
It is possible that OPG, which we used to modulate OCL activity, may also affect 
endothelial cells.  Several studies have reported possible direct stimulatory effects of OPG on 
endothelial cells, suggesting that we may have underestimated the contribution of OCLs to 
angiogenesis in our experiments using OPG.[67-69]  Further, OPG can stimulate angiogenesis or 
endothelial cell survival in cell culture or aortic ring explants.[135, 220]  In agreement with these 
findings, when equivalent concentrations of OPG to those used to inhibit metatarsal angiogenesis 
were tested in the HUVEC / fibroblast co-culture angiogenesis assay, which lacks OCLs, we 
observed a slight stimulation rather than any inhibition of angiogenesis in the HUVEC cultures.  
It is unclear if PTHrP can directly inhibit or stimulate endothelial cells.  Two studies reported 
PTHrP inhibited and one reported PTHrP stimulated endothelial cells.[67-69]  Like PTHrP, it is 
unclear if RANKL has  possible direct effects on endothelial cells.[132, 135]   
In the studies described in the following chapter, we investigated the mechanisms 
required for OCLs to stimulate angiogenesis and found that MMP-9 is required for OCL 
stimulated angiogenesis in metatarsal explants and in vivo.    
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3.0  OSTEOCLAST-STIMULATED ANGIOGENESIS REQUIRES MMP-9 
3.1 SUMMARY 
The studies in this chapter investigate the molecular mechanisms underlying OCL-
stimulated angiogenesis.  We first reviewed the literature and studied the expression of 
angiogenic factors by OCLs to determine which molecules may be used by OCLs to stimulate 
angiogenesis.  Three factors we investigated, IL-8, MCP-1 and osteopontin, were not important 
for OCL-stimulated angiogenesis in the HUVEC / fibroblast in vitro angiogenesis assay.  Most 
of the studies in this chapter investigate whether MMP-9 is important for OCL stimulated 
angiogenesis.  MMP-9 was a logical choice for the mediator of OCL-stimulated angiogenesis for 
several reasons.  It is expressed highly by OCLs and was expressed by OCLs almost 100 fold 
higher than any other angiogenic factor on the SA Biosciences human angiogenesis Q-PCR 
array.  Importantly, it is primarily expressed by OCLs in bone.  It is known to stimulate 
angiogenesis by release of matrix bound VEGF.  We studied the role of MMP-9 in OCL-
stimulated angiogenesis using all three of the model systems described in chapter 2.  Lack of 
MMP-9 reduced OCL stimulated angiogenesis in metatarsal explants as shown by loss of the 
pro-angiogenic response to PTHrP.  Likewise, lack of MMP-9 also reduced OCL-stimulated 
angiogenesis in calvaria in vivo as shown by a blunted angiogenic response to RANKL.  
Interestingly, PTHrP or RANKL stimulated osteoclasts less in MMP-9-/- than WT metatarsal 
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explants and calvaria in vivo.  However, the number of vessels per OCL was not reduced by lack 
of MMP-9 in vivo and lack of MMP-9 did not decrease OCL formation from bone marrow cells  
in vitro.  A neutralizing antibody to MMP-9 did not block the pro-angiogenic activity of MMP-9 
conditioned media.  From these data we concluded that MMP-9 is required for OCL-stimulated 
angiogenesis primarily due to its known effects on OCL migration.                
3.2 INTRODUCTION 
A search of the literature showed that OCLs secrete many different angiogenic factors, 
which can act directly on endothelial cells, including VEGF, IL-8, osteopontin, bFGF, PDGF, 
Angiopoietin-1 and Angiopoietin-2.[6, 119-123]  Furthermore, during the course of our studies, 
Tanaka et al reported that OCLs stimulate angiogenesis in vitro due to secretion of 
osteopontin.[5]  All of these molecules would be expected to stimulate angiogenesis by acting 
directly on endothelial cells.   
 However, there are many ways in which OCLs could stimulate angiogenesis more 
indirectly.  They could release angiogenic factors from calcified or non-calcified matrix.  For 
example, osteoclastic resorption is theorized to release active TGF-β from bone matrix.[10]  This 
observation has led to a large body of literature on the “viscious cycle” of cancer bone 
metastasis.[109]  Secondly, increased OCL number and activity could lead to proliferation or 
increased angiogenic factor expression in another cell type which would then secrete the direct 
stimulators of angiogenesis.  For example, in most physiological situations, increases in OCL 
number are coupled to increased osteoblastogenesis.  The ability of osteoblasts to stimulate 
angiogenesis is well known.[15]       
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Early studies in MMP-9-/- mice suggested that OCLs may stimulate angiogenesis by 
secretion of MMP-9, but the hypothesis has not been further pursued.  MMP-9-/- mice display 
delayed endochondral ossification and vessel invasion into the primary ossification center, 
accompanied by lengthened growth plates.  However, this phenotype resolves, and adults have 
normal appearing bones, which are slightly shorter than in WT animals.[14]  These investigators 
soon delineated the mechanism for the effects of MMP-9 on OCL invasion and reported that 
MMP-9 release of matrix bound VEGF is important for OCL recruitment to the long bone 
growth plate.  MMP-9 decreased resorption in E17 mouse metatarsal explants, but not in more 
mature bones.  These effects were due to the effects of MMP-9 on invasion or migration rather 
than matrix solubilization.[161]  Likewise, others reported MMP-9 is important for OCL or OCL 
precursor migration in vitro.[253-255]  Similarly, MMP-9 delays OCL and vessel invasion into 
long bone fracture calluses.[164]  In bone, MMP-9 is predominantly expressed by OCLs and 
committed OCL precursors, but can be expressed by other cell types such as osteoblasts and 
hypertrophic chondrocytes during development, and macrophages and neutrophils during 
fracture repair.[14, 164, 248, 276]  Therefore, OCLs are likely responsible for most of the effects 
of MMP-9 in bone.   
Several studies have reported that MMP-9 stimulates angiogenesis through activation or 
release of growth factors.  MMP-9 was first implicated as the angiogenic switch in a mouse 
pancreatic cancer model in which MMP-9 released matrix (heparan) associated VEGF and 
increased VEGF signaling.[12]  Likewise, MMP-9 expression and resultant VEGF activation by 
macrophages was required for angiogenesis in a cervical cancer model.[13]      
 We studied the mechanisms of OCL-stimulated angiogenesis by first studying 
OCL expression of angiogenic factors, then testing likely candidates for their importance to OCL 
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mediated angiogenesis.  We found that MMP-9 is important for OCL stimulated angiogenesis in 
metatarsal explants and in vivo primarily due to its effect on OCL migration.   
3.3 MATERIALS AND METHODS 
Materials:  Primary antibodies: Polyclonal rabbit anti-mouse MMP-9 was purchased from 
Abcam (#ab38898).  The 11b5 mouse monoclonal IgM anti-VEGF-A in complex with VEGFR-1 
or R-2 antibody was obtained from East Coast Bio (#CD302).  Secondary antibodies:  Vector 
Laboratories supplied biotinylated goat anti-rabbit secondary antibodies and SA-HRP.  Jackson 
ImmunoResearch supplied biotinylated goat anti-mouse IgM μ chain and goat movalent Fab 
anti-mouse μ chain (for blocking endogenous IgM).  Mouse anti-human MMP-9 neutralizing 
antibody clone # 6-6B (cat # IM09L) was provided by Calbiochem.  Recombinant human 
osteopontin rh IL-8, rh MCP-1, rh VEGF165, mouse monoclonal anti human IL-8 neutralizing 
antibody (clone #6217)  and “Quantikine” ELISA assays for human osteopontin, MCP-1 and IL-
8  were from R&D Systems.  RNA Bee (phenol chloroform) RNA purification reagent was from 
Tel-Test.  cDNA synthesis and PCR reagents (Superscript II reverse transcriptase, oligo dT, first 
strand buffer, DTT, Taq DNA polymerase, PCR buffer, dNTPs, and MgCl2) were from 
Invitrogen.  Human angiogenesis quantitative real-time PCR array and RT2 cDNA synthesis kit 
were from SA Biosciences.  RNeasy RNA purification kit was from Qiagen.  MMP-9-/- mice 
were generated as described and backcrossed to C57BL/6 mice for 10 generations.[14]  Timed 
pregnant C57BL/6 mice were from The Jackson Laboratory.       
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Analysis of Human OCL angiogenic factor expression by reverse transcriptase 
PCR:  Human bone marrow OCLs were cultured as described in chapter 2.  Total RNA was 
purified using RNA Bee (phenol chloroform extraction).  1 μg total RNA was reverse transcribed 
using Superscript II reverse transcriptase.  PCR was performed on a Applied Biosystems 
GeneAmp 2700 thermocycler with the following program: initial incubation for 5 minutes at 
95°C followed by 35 to 40 cycles of denaturing at 95°C for 1 minute, indicated annealing 
temperature for 1 minute, and extension at 72°C for 1 minute followed by a final extension for 
10 minutes at 72°C.  Products were visualized on 2% agarose gels stained by soaking in 1 μg/ml 
ethidium bromide in TAE buffer.  PCR for β-actin was performed to verify successful cDNA 
synthesis and confirm negative results.   
 
Table 3.1.  Primers used for analysis of human OCL angiogenic factor expression by reverse 
transcriptase PCR 
Gene Sequence Size 
(bp) 
Annealing 
Temperature 
VEGFA Sense           5’  gaaaccatgaactttctgc 
Antisense    5’  cgcctcggcttgtca 
470, 
602, 674 (3 
splice 
isoforms) 
50°C 
FGF2 Sense           5’  agcggctgtactgcaaaaac 
Antisense    5’  cccaggtcctgttttggat 
338 57°C 
 
ANGPT1 Sense          5’  aaatggaaggaaaacacaaggaa 
Antisense    5’  atctgcacagtctctaaatggt 
263 58°C 
ANGPT2 Sense           5’  ggatctggggagagaggaac 
Antisense    5’  ctctgcaccgagtcatcgta 
535 60°C 
ANGPT4 Sense           5’  cccagatgccagagaccttt 
Antisense    5’  cacctgctcacctgccatta 
368 60°C 
IL8 Sense           5’  cgatgtcagtgcataaagaca 
Antisense    5’  tgaattctcagccctcttcaaaaa 
201 57°C 
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Human OCL culture angiogenic factor array analysis:  For comparison of the profile 
of angiogenic factors expressed in human OCL or macrophage culture, OCLs were cultured as 
described in chapter 2 with the following modifications:  non-adherent cells were diluted to 2 x 
106 / ml in α-MEM with 20% horse serum, 10 ng/ml rh M-CSF with or without 50 ng/ml rh 
RANKL and seeded 0.4 ml per well of 48 well plates.  Cultures were maintained for 17 days 
with twice weekly changes of half the media volume containing a full complement of cytokines, 
as previously described.[19]  Expression of angiogenic factors was determined in OCL (RANKL 
+ M-CSF treated) vs control cultures cultured with M-CSF only using the SA biosciences real 
time Q-PCR human angiogenic factor array.  For replicates of the profile of angiogenic factors 
expressed in human purified OCLs, cultures were performed as described in chapter 2.   
RNA (primarily mRNA) was purified with Qiagen RNeasy kit and reverse transcribed 
with the SA biosciences RT2 first strand kit.  Real time PCR was performed on a BioRad I-
Cycler with provided primers and SYBR green.  Ct values were calculated by the default settings 
of the I-Cycler software.  Genomic DNA controls were negative.  Data was analyzed by the 
ΔΔCt method compared to the average Ct value of the 4 or 5 housekeeping genes.  Expression of 
each gene relative to housekeeping genes was calculated as 2-ΔCt.  Genes that had Ct values of 
higher than 35 cycles were considered not expressed and not analyzed.  The following genes 
were included on the array:  
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Table 3.2.  Genes analyzed on the SA Biosciences human angiogenesis array. 
Group Gene Symbol Description Aliases 
ANGPT1 Angiopoietin-1  
ANGPT2 Angiopoietin-2  
TYMP Thymidine phosphorylase ECGF1, PDECGF1 
ANPEP Alanyl aminopeptidase APN, CD13 
 
EREG Epiregulin  
FGF1 Fibroblast growth factor 1  
FGF2 Fibroblast growth factor 2 Basic FGF 
FIGF c-fos induced growth factor VEGF-D 
FLT1 Fms-like tyrosine kinase 1 VEGF-R1 
JAG1 Jagged 1  
KDR Kinase insert domain receptor Flk-1, VEGF-R2 
LAMA5 Laminin alpha 5  
NRP1 Neuropilin-1  
NRP2 Neuropilin-2  
PGF Placental growth factor PlGF, PLGF-2 
PLXDC1 Plexin domain containing 1  
STAB1 Stabilin-1  
VEGFA Vascular endothelial growth 
factor 
VEGF, VPF 
VEGFC Vascular endothelial growth 
factor C 
 
S1PR1 Sphingosine-1-phosphate 
receptor-1 
EDG-1 
EFNA-1 Ephrin-A1  
EFNA-3 Ephrin-A3  
EFNB2 Ephrin-B2  
EPHB4 EPH receptor B4 Ephrin receptor 
EphB4 
EGF Epidermal growth factor  
FGFR3 Fibroblast growth factor 
receptor 3 
 
HGF Hepatocyte growth factor  
IGF1 Insulin like growth factor 1  
PDGFA Platlet derived growth factor, 
alpha polypeptide 
PDGF A-chain 
TEK TEK tyrpsine kinase, 
endothelial 
Tie-2 
TGFA Transforming growth factor 
alpha 
 
TGFB1 Transforming growth factor 
beta 1 
TGF-β1 
Growth factors and 
receptors 
TGFB2 Transforming growth factor  
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beta 2  
TGFBR1 Transforming growth factor 
beta, receptor 1 
 
ANGPTL3 Angiopoietin-like 3 ANGPT5 
BAI1 Brain specific angiogenesis 
inhibitor-1 
 
COL4A3 Collagen type 4, alpha 3 Tumstatin 
CDH5 Cadherin 5, type 2 VE-Cadherin 
COL18A1 Collagen, type XVIII, alpha 1 Endostatin 
ENG Endoglin  
ITGAV Alpha v integrin  
ITGB3 Beta 3 integrin  
THBS1 Thrombospondin-1  
Adhesion 
Molecules 
THBS2 Thrombospondin-2  
ANGPTL4 Angiopoietin-like 4 ANGPTL2/ARP4 
PECAM1 
Platelet/endothelial cell 
adhesion molecule (CD31 
antigen) CD31 
PF4 Platelet factor 4 CXCL4/SCYB4 
PROK2 Prokineticin 2 BV8/KAL4 
   
Gene Symbol Description Aliases 
SERPINF1 
Serpin peptidase inhibitor, 
clade F (alpha-2 antiplasmin, 
pigment epithelium derived 
factor), member 1 PEDF 
TNFAIP2 
Tumor necrosis factor, alpha-
induced protein 2 B94 
HPSE Heparanase HPA/HPR1 
LECT1 
Leukocyte cell derived 
chemotaxin 1 BRICD3/CHM-I 
LEP Leptin OB/OBS 
MMP2 Matrix metallopeptidase 2  Gelatinase A 
MMP9 Matrix metallopeptidase 9  Gelatinase B 
PLAU 
Plasminogen activator, 
urokinase uPA 
PLG Plasminogen  
TIMP1 
TIMP metallopeptidase 
inhibitor 1  
TIMP2 
TIMP metallopeptidase 
inhibitor 2  
Proteinases, 
Proteinase 
Inhibitors and 
other Matrix 
proteins 
 
 
 
 
Proteinases, 
Proteinase 
Inhibitors and 
other Matrix 
proteins 
(continued) 
TIMP3 
TIMP metallopeptidase 
inhibitor 3   
Cytokines and 
Chemokines CCL11 
Chemokine (C-C motif) ligand 
11 SCYA11 
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CCL2 
Chemokine (C-C motif) ligand 
2 GDCF-2/GDCF-2  
CXCL1 
Chemokine (C-X-C motif) 
ligand 1  GRO1/GROa 
CXCL10 
Chemokine (C-X-C motif) 
ligand 10 C7/IFI10 
CXCL3 
Chemokine (C-X-C motif) 
ligand 3 CINC-2b/GRO3 
CXCL5 
Chemokine (C-X-C motif) 
ligand 5 ENA-78/SCYB5 
CXCL6 
Chemokine (C-X-C motif) 
ligand 6 (granulocyte 
chemotactic protein 2) CKA-3/GCP-2 
CXCL9 
Chemokine (C-X-C motif) 
ligand 9 CMK/Humig 
IFNA1 Interferon, alpha 1 IFL/IFN 
IFNB1 Interferon, beta 1, fibroblast IFB/IFF 
IFNG Interferon, gamma IFG/IFI 
IL6 Interleukin 6 BSF2/HGF 
IL8 Interleukin 8 3-10C/AMCF-I 
MDK Midkine MK/NEGF2 
 
TNF Tumor necrosis factor  DIF/TNF-alpha 
HAND2 
Heart and neural crest 
derivatives expressed 2 DHAND2/Hed 
SPHK1 Sphingosine kinase 1 SPHK 
AKT1 V-akt  AKT/PKB 
HIF1A 
Hypoxia-inducible factor 1, 
alpha subunit  HIF-1alpha 
ID1 Inhibitor of DNA binding 1 ID 
ID3 Inhibitor of DNA binding 3 HEIR-1 
NOTCH4 Notch homolog 4 (Drosophila) INT3/NOTCH3 
Transcription 
factors and others 
PTGS1 
Prostaglandin-endoperoxide 
synthase 1  COX1/COX3 
B2M Beta-2-microglobulin B2M 
HPRT1 
Hypoxanthine 
phosphoribosyltransferase 1  HGPRT/HPRT 
RPL13A Ribosomal protein L13a RPL13A 
GAPDH 
Glyceraldehyde-3-phosphate 
dehydrogenase G3PD/GAPD 
Housekeeping 
Genes 
ACTB Actin, beta PS1TP5BP1 
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Fetal Mouse Metatarsal Angiogenesis Assay:  General assay procedures are described 
in chapter 2.  Images of CD31 stained explants were acquired with an Olympus Multimode 
dissecting microscope and were quantified either with ImageJ for total CD31+ area and corrected 
for the area of bones stained with control IgG in place of primary antibody.  For comparing the 
angiogenic and osteoclastic response of MMP-9 -/- vs. wt metatarsals treated with PTHrP, 7 
litters of C57BL/6 and 6 litters of C57BL/6 MMP-9 -/- were treated with 100 nM PTHrP or 
solvent separately.  The mean fold increase in CD31+ area with PTHrP treatment was calculated 
for each litter.  The effect of PTHrP treatment on each genotype was compared by calculating the 
mean increases (fold control) per litter.  This analysis was necessitated by the large variability in 
angiogenesis that was seen among litters in solvent treated explants.   
 
Histology and Immunohistochemistry:  Labeling of CD31 and TRAP in fixed frozen 
sections was performed as described in chapter 2.  For 11b5 labeling, blocking was accomplished 
with 10% goat serum, 1% horse serum (HS) PBS, followed by PBST washes x2. Blocking of 
endogenous IgM was accomplished with Fab anti-μ 0.1 mg/mL in PBS, followed by primary 
antibody (culture supernatant 1:10 in 1% HS-PBS), 1% HS-PBS washes x5, goat anti-μ in 1% 
HS-PBS, PBS washes x5 and SA-HRP and substrate as above.   
 
In vivo studies:  MMP-9-/- C57BL/6 mice were injected with m RANKL-GST along side 
the WT mice described in chapter 2.  Data from WT mice is reported again in this chapter and 
compared to MMP-/- mice.    
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In vitro angiogenesis assay:  Human OCL conditioned media was collected and the TCS 
CellWorks in vitro angiogenesis assay was performed as in chapter 2.  For MMP-9 
neutralization, neutralizing antibody clone # 6-6B or moue IgG control were diluted to a final 
concentration of 3 μg/mL and pre-incubated for 1 hour at 37oC.  This concentration is 3 fold 
higher than the concentration reported to inhibit MMP-9 activity in bioassays.[277]        
 
Statistical Analyses:  The unpaired Student’s t-test or one way ANOVA with LSD 
procedure were used for analyzing 2 or multiple groups respectively.  The ratio t-test (paired t-
test on logarithms of vehicle vs treated samples) was used for analysis fold control data.  Two-
tailed analyses were performed with SPSS software.  Significance was set at α = 0.05.    
3.4 RESULTS   
3.4.1     Analysis of OCL Angiogenic Factor Expression
 
 
 
 
We  analyzed  gene  expression  of   angiogenic  factors   in  human   OCL  cultures  by  reverse 
transcriptase PCR and the SA Biosciences quantitative real time PCR human angiogenesis array.
We took a candidate factor  approach in the reverse transcriptase PCR  studies.  The results of
these studies are  shown  in Figure 3.1.   Purified human OCL  cultures expresses angiopoietin-1,                                          
angiopoietin-4, and FGF-2, but did not express VEGF or angiopoietin-2. 
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Figure 3.1.  Analysis of osteoclast angiogenic factor expression by reverse transcriptase PCR 
RNA collected from human bone marrow OCL cultures or control cell types was analyzed by reverse 
transcriptase PCR 
 
To analyze angiogenic factor gene expression of human OCLs on a wider scale, we used 
the SA Biosciences human angiogenesis real Q-PCR array.  To determine the angiogenic factors 
expressed by OCLs, the level of angiogenic factor expression in two independent purified human 
OCL cultures was analyzed.  The 15 most highly expressed angiogenic factors in both cultures 
are reported in table 3.3.  The following genes were in the top 15 in both groups.:  MMP-9, 
TIMP1, TIMP2, MCP-1, ANPEP, HIF1-α, αv integrin, NRP1, NRP2 and IL-8.   
 
Table 3.3.  15 most highly expressed angiogenic factors (or inhibitors) in 2 purified human OCL 
cultures.  
Expression is reported relative to the 4 housekeeping genes: HPRT1, RPL13A, GAPDH and 
ACTB.   
Culture # 1 Culture # 2 
Gene Relative Expression Gene Relative Expression 
MMP9 19.69831 MMP9 15.45498 
TIMP2 0.870551 TIMP1 1.931873 
ANPEP 0.659754 CCL2 (MCP-1) 0.68302 
CCL2 (MCP-1) 0.466516 TIMP2 0.392292 
HIF-1a 0.435275 IL-8 0.34151 
alphaV integrin 0.307786 ANPEP 0.31864 
Endoglin 0.267943 AlphaV integrin 0.31864 
TIMP1 0.217638 CXCL9 (MIG) 0.241484 
uPA 0.176777 TNF-a 0.129408 
TGFB1 0.164938 HIF-1a 0.098073 
NRP1 0.143587 NRP2 0.056328 
NRP2 0.076947 NRP1 0.03983 
IL-8 0.058315 CXCL10 0.03983 
CXCL5 (ENA-78) 0.044194 Beta3 Integrin 0.03983 
ECGF1 0.044194 CXCL1 (GRO-alpha) 0.037163 
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Alternatively, to analyze angiogenic factors induced by OCL differentiation, we 
compared angiogenic factor expression in human bone marrow non-adherent cell OCL cultures 
(cultured with RANKL and M-CSF) compared with cells cultured with M-CSF alone containing 
mostly macrophages.  Genes upregulated at least 4 fold in OCL relative to control cultures are 
reported in Table 3.4.  Expression of angiopoietin-2 was not observed by conventional reverse 
transcriptase PCR but was detected on the array at a very low level.    
 
Table 3.4.  Angiogenic Factors Upregulated by OCL differentiation 
* Expression of angiogenic factors relative to 5 housekeeping genes: B2M, HPRT1, RPL13A, GAPDH and 
ACTB in OCLs cultured from human bone marrow adherent cells treated with RANKL and M-CSF was assayed 
with the SA Biosciences human angiogenesis Q-PCR array. 
† The fold expression in human bone marrow OCL cutltures relative to human bone marrow adherent cells 
cultured with M-CSF only was calculated normalized to housekeeping genes.  Only factors upregulated at least 4 
fold are reported.    
 
Angiogenic factor OCL expression 
relative to 5 housekeeping 
genes* 
Fold upregulation 
compared to M-CSF treated 
cultures† 
MMP-9 47 7.1 
ANPEP (APN, CD13) 0.48 4.1 
β3 integrin 0.069 28.2 
MMP-2 0.069 7.1 
Neuropilin-2 0.060 5.7 
Sphingosine Kinase 1 0.020 11 
CXCL5 (ENA-78) 0.012 8.1 
Notch-4 0.0061 5.0 
COL18A1 (endostatin) 0.0026 8.1 
Angiopoietin-2 0.00020 4.1 
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As shown in Table 3.3 and 3.4, MMP-9 was much more highly expressed in OCLs than 
the other genes analyzed.  MMP-9 was the most highly expressed pro-angiogenic factor by 
human OCLs at the mRNA level and was expressed approximately an order of magnitude more 
highly than all other angiogenic factors examined. It was also upregulated over 7 fold compared 
to control cultures of primarily macrophages treated only with M-CSF. 
3.4.2 MMP-9 is Required for OCL Stimulation of Angiogenesis in Metatarsal Explants 
Because MMP-9 can be pro-angiogenic, is expressed highly by OCLs, and its null allele delays 
blood vessel invasion of the growth plate, we next determined if OCLs stimulate angiogenesis in 
part by secretion of MMP-9.   
We tested the capacity of PTHrP to stimulate angiogenesis in metatarsal explants from 
MMP-9-/- or WT C57BL/6 mice by treating metatarsals from 7 WT and 6 MMP-9-/- C57BL/6 
litters of mouse embryos with 100 nM PTHrP (1-34) or vehicle and comparing the ability of 
PTHrP to stimulate angiogenesis as measured by CD31+ area.  Because of the large variability in 
the level of basal angiogenesis and resorption among litters, angiogenesis and OCL activity data 
were analyzed in terms of fold control for each litter.  As indicated by the positive (ratio greater 
than unity) effects of PTHrP vs. vehicle, PTHrP increased angiogenesis in WT but not in MMP-
9-/- metatarsal explants, and the angiogenic effects differed between the genotypes (Figure 3.2A, 
3.2B).   
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 Figure 3.2.  MMP-9 is required for OCL-stimulated angiogenesis in metatarsal explants. 
PTHrP-induced metatarsal angiogenesis is blunted in MMP-9-/- explants.  Sample 2x original magnification 
images of WT or MMP-9 -/- C57BL/6 metatarsal explants treated with vehicle or 100 nM PTHrP as indicated and 
stained for CD31.  Images acquired as in figure 2.  (B)  Angiogenic response to PTHrP is significantly less in MMP-
9-/- than in WT metatarsal explants.  Metatarsals from 7 WT and 6 MMP-9-/- litters of each genotype were treated 
with 100 nM PTHrP or vehicle.  The mean increase in CD31+ area per litter for all litters ± SEM is reported.  *:  p < 
0.05. for difference in treatment response between genotypes.  PTHrP significantly stimulated angiogenesis in WT 
 83 
but not in MMP-9-/- metatarsals, as determined by the ratio t-test comparing vehicle and PTHrP treated means for 
each litter.   
3.4.3 MMP-9 is Required for OCL Stimulation of Angiogenesis in vivo 
We stimulated OCL formation in both WT and MMP-9-/- C57BL/6 mice by supra-calvarial 
injection of RANKL to determine if OCLs increased angiogenesis by a mechanism requiring 
MMP-9.  RANKL treatment induced dramatic changes in bone resorption and OCL formation in 
the outer table (Figure 3.3A).  The resorbed area was replaced by non-calcified tissue resembling 
active periosteum and contained newly formed vessels not previously present in calcified tissue.  
Angiogenesis was induced by RANKL only in WT but not MMP-9-/- calvaria as measured by 
CD31+ vessel density or total CD31+ vessel area within the outer table of calvaria (Figure 3.3B).  
Angiogenesis in WT calvaria treated with RANKL was significantly different from RANKL 
treated MMP-9-/- calvaria when angiogenesis was quantified by vessel density, and nearly 
significant when angiogenesis was quantified by total vessel area.  As with calvaria treated with 
PTHrP no significant differences in vessel size were detected (data not shown).  MMP-9 was 
primarily expressed by OCLs, thus suggesting the MMP-9 important for OCL-stimulated 
angiogenesis is derived from OCLs themselves (Figure 3.3A).   Surprisingly, the 
osteoclastogenic response to RANKL was blunted in MMP-9-/- calvaria (Figure 3.3A).  This 
suggests that MMP-9 affects OCL-stimulated angiogenesis by decreasing the number of OCLs at 
the angiogenic site and will be analyzed in more detail in the next section.       
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 Figure 3.3.  Osteoclasts stimulate angiogenesis in WT but not MMP-9-/-  mice 
(A)  Supra-calvarial RANKL increases angiogenesis and MMP-9 expressing OCL formation to a greater 
extent in calvaria of wild type than MMP-9-/- mice.  Serial sections of the outer table of calvaria stained for TRAP 
(red) and CD31 (brown) or MMP-9 (brown) and lightly counterstained with hematoxylin.  Images are WT or MMP-
9 KO injected supracalvarially with vehicle or m RANKL-GST as indicated.  Arrows: CD31+ vessels in remodeling 
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bone.  Outer surface is at the top of the image.  (B)  Quantification of RANKL induced vessel response by 
calculation of CD31+ vessel density or area in the outer table of 10x objective images taken at the calvarial midline.   
3.4.4 MMP-9 Stimulates Bone Angiogenesis Primarily through Autocrine Effects on OCL 
Migration 
To further analyze the source of the MMP-9 responsible for the pro-angiogenic response of 
RANKL treatment in calvaria, I then determined the cell types expressing MMP-9 in the marrow 
spaces of mouse calvaria by singly or double labeling TRAP and MMP-9.  MMP-9 expression 
was almost completely restricted to OCLs.  Immunohistochemical analysis of mouse calvaria 
showed that MMP-9 was almost completely co-localized with the OCL marker TRAP (Figure 
3.4).  Only very rare MMP-9 positive, TRAP negative mononuclear marrow cells were detected.     
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 Figure 3.4.  MMP-9 is predominantly expressed by osteoclasts in mouse calvaria. 
Coronal sections of mouse calvaria stained for TRAP (red) or MMP-9 (brown) as indicated.  Images 
acquired with a Nikon Eclipse E800 microscope with a Plan Apo objective (oil), NA of 1.4 and an Olympus 
America SN CG603057-H camera with Magnifire software.  Original magnification x 60.   
 
In the experiments comparing the angiogenic effects of OCL stimulation in explants or in 
vivo (Figure 3.2 and 3.3), I also analyzed the osteoclastic responses to determine if lack of MMP-
9 affected OCL formation or recruitment.  Osteoclast stimulation induced by PTHrP or RANKL 
was blunted in MMP-/- mice.  Type I collagen C-terminal telopeptide (CTX), were measured in 
the conditioned media collected from days 1-3 and 4-6 of culture from all WT and MMP-9-/- 
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PTHrP and vehicle treated explants.  PTHrP significantly stimulated bone resorption in WT 
explants at both time points.  However, PTHrP did not significantly stimulate resorption at 3 or 6 
days in MMP-9-/- explants (Figure 3.5).  Other investigators similarly reported lack of MMP-9 
decreased OCL resorption in E17 metatarsal explants due to OCL migration or invasion 
defects.[161, 253] 
 
 
Figure 3.5.  PTHrP increases bone resorption in WT but not in MMP-9-/- metatarsal explants.   
CTX assayed from conditioned media collected from days 1-3 or 4-6 of culture of all 7 WT and 6 KO 
litters.  *:  p < 0.05. for treatment response compared to vehicle. 
 
In parallel to our findings in metatarsal explants treated with PTHrP, OCL formation was 
stimulated by RANKL in WT but less so in MMP-9-/- animals in the calvarial outer table (Figure 
3.6A).  Resorption surface or TRAP+ area was significantly less in RANKL treated MMP-9-/- 
than RANKL treated WT calvaria.  The OCL stimulation with RANKL among MMP-9-/- mice 
was dramatically blunted compared to WT animals and possibly absent.  However, we were not 
able to find any reports in the literature that MMP-9 affects OCL differentiation directly.  
Therefore, to determine if the decrease in OCL numbers in RANKL treated MMP-9-/- mice 
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results from decreased OCL differentiation or precursor number, we assayed OCL differentiation 
in vitro and found that WT and MMP-9-/- mice formed similar numbers of OCLs (Figure 3.6B).  
To examine the relative angiogenic capacity of MMP-9-/- OCLs on a per cell basis, we calculated 
vessel number per OCL, which did not differ between genotypes (Figure 3.6C).  Thus, MMP-9 is 
not of primary importance for OCLs to stimulate angiogenesis per se, but affects OCL numbers 
at the angiogenic site.  Thus, MMP-9 most likely affects OCL-stimulated angiogenesis primarily 
by affecting their migration to the angiogenic site.  
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Figure 3.6.  Lack of MMP-9 decreases RANKL-stimulated osteoclastogenesis in vivo but not in vitro.  
(A)  Total percent TRAP+ area of the calvarial outer table or resorptive surface of the outer table sub-
periosteal surface.  (B)  In vitro Osteoclast formation from bone marrow from WT and MMP-9-/- C57BL/6 mice was 
quantified by counting TRAP+ multi-nucleated cells.  (C)  Vessels per OCL was calculated by dividing vessel 
density by TRAP+ area for each RANKL treated animal.  Mean ± SEM.  *:  p < 0.05.   
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Because MMP-9 is known to stimulate angiogenesis by VEGF release from matrix in 
other tissues, we determined if VEGF signaling was increased with OCL stimulation in vivo.  
Increased VEGF signaling induced by proteases such as MMP-9 can be analyzed using 
monoclonal antibodies which recognize VEGF only in complex with its receptors.  Therefore we 
determined the number of VEGF / receptor complex positive vessels using the 11b5 monoclonal 
antibody, which recognizes VEGF in complex with VEGF-R1 or R2.[278]  Labeling with this 
antibody, we found that PTHrP non-significantly increased 11b5+ vessel density (Figure 3.7B).  
The labeling of 11b5+ vessels was less clearly defined than CD31+ vessels, suggesting that other 
cell types in addition to endothelial cells, such as pericytes, are also labeled (Figure 3.7A).  A 
minority of the vessels were 11b5+, as illustrated by the observation that the 11b5+ vessel density 
was only about 20% of the CD31+ vessel density (Figure 3.7A and comparing Figures 3.7B and 
2.4C).  In some highly angiogenic states linked to MMP-9, greater than 90% of vessels are 
VEGF / receptor complex positive.[13]  Furthermore, we were unable to detect 11b5+ vessels 
induced in angiogenic areas of the calvaria outer table from animals treated with RANKL (same 
areas as illustrated in Figure 3.3).  Therefore, these data suggest that increased VEGF signaling 
due to release from matrix may contribute to OCL induced angiogenesis, but other mechanisms 
are likely to be involved.   
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 Figure 3.7.  PTHrP may increase VEGF signaling in vivo.   
VEGF / receptor complex positive vessels in PTHrP treated calvaria.  (A) Para-sagittal marrow spaces in 
vehicle or PTHrP treated calvaria. Sections stained for VEGF / receptor complexes with the 11b5 monoclonal 
antibody (brown), TRAP (red) and counterstained with hematoxylin.  Arrows: 11b5+ vessels.  Arrowheads: 11b5 
negative vessels.  Original magnification x 60 (B)  Number of 11b5+ vessels per mm2 of para-sagittal marrow area.  
Mean ± SEM.   
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3.4.5 MMP-9, MCP-1, IL-8 or Osteopontin Are Not Required for Angiogenic Activity of 
OCL Conditioned Media 
To further verify the mechanism used by OCL to stimulate angiogenesis, we examined the 
angiogenic activity of candidate angiogenic factors secreted by OCL using the HUVEC / 
fibroblast in vitro angiogenesis assay.  These experiments suggested that none of these factors 
are important on their own for angiogenic action of OCLs directly upon endothelial cells. 
We examined possible direct angiogenic activity of OCL-derived MMP-9 with a 
neutralizing antibody to MMP-9 in vitro, using an antibody concentration 3 fold higher than 
previously reported to neutralize MMP-9 activity.[277]  Neutralization of MMP-9 activity did 
not affect angiogenesis in the basal state. When stimulated by OCL conditioned media MMP-9 
inhibition surprisingly had a slight stimulatory effect on angiogenesis (Figure 3.8).  Thus, OCL-
derived MMP-9 is unlikely to stimulate endothelial cells directly.   
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Figure 3.8.  MMP-9 inhibition does not decrease the angiogenic activity of osteoclast conditioned 
media in vitro.  
Concentrated OCL conditioned media or control media was combined with angiogenesis assay media and 
pre-incubated with 3 μg/ml neutralizing anti-MMP-9 or control IgG for 1 hour at 37°C, then used to stimulate the 
HUVEC / fibroblast angiogenesis assay.  The assay was stained for CD31 and angiogenic tube formation was 
quantified with Metamorph software.    
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Because Tanaka et al reported that osteopontin is important for the angiogenic activity of 
OCLs in the HUVEC / fibroblast in vitro angiogenesis assay, we tested the angiogenic activity of 
recombinant osteopontin in the same assay.[5]  However, we were not able to replicate their 
results that 1 μg/ml rh osteopontin stimulated angiogenesis (Figure 3.9).  In our system, the 
working concentration of osteopontin derived from OCL conditioned media is also 
approximately 1 μg/ml as measured by ELISA (data not shown). 
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 Figure 3.9.  Recombinant osteopontin does not stimulate angiogenesis in vitro.  
2 μg / ml rh VEGF or indicated concentrations of rh osteopontine were added to the HUVEC / fibroblast 
angiogenesis assay.  Mean ± SEM *:  p < 0.05 from media control. 
 
In the human OCL angiogenesis arrays, IL-8 and MCP-1 were the most highly expressed 
non-proteinase angiogenic factors.  Therefore, I also investigated if they were important for the 
angiogenic activity of OCL conditioned media.  I first performed ELISA experiments to 
determine the concentrations of MCP-1 and IL-8 secreted by OCLs.  IL-8 was low ng / ml and 
MCP-1 was at high pg / ml at the working concentrations in OCL CM used for in vitro 
angiogenesis assays (data not shown). 
To determine if IL-8 was required for the pro-angiogenic activity of human OCL 
conditioned media, I first performed an IL-8 dose response curve in the presence or absence of 
IL-8 neutralizing antibody.  I chose a concentration range that was obtainable using human OCL 
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conditioned media.  I did not observe any stimulatory effect at rh IL-8 concentrations up to 9 
ng/ml (Figure 3.10A).  Curiously, 1 ng/ml IL-8 slightly inhibited angiogenesis.  This suggests 
that human OCLs probably do not secrete enough IL-8 under these conditions to explain their 
stimulation of the assay.  In a separate experiment, no stimulation was seen with 100 ng / ml IL-8 
(data not shown).     
Similarly, I also neutralized IL-8 in OCL conditioned media added to the human in vitro 
angiogenesis assay (Figure 3.10B).  As was suggested by the IL-8 dose response curve, IL-8 
neutralization had no effect on the capacity of OCL conditioned media to stimulate angiogenesis.  
However, IL-8 neutralization did reduce the stimulation of the assay by recombinant VEGF.  
This observation may be due to inhibition of endothelial cell autocrine IL-8.[239]  Thus, IL-8 
does not appear to be an important factor in OCL stimulation of angiogenesis.   
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 Figure 3.10.  IL-8 is not responsible for the angiogenic activity of osteoclast conditioned media.   
(A)  rh VEGF165 (2 ng/mL) or rh IL-8 was added to the HUVEC / fibroblast in vitro angiogenesis assay 
after a 30 minute pre-incubation at the indicated concentrations with mouse IgG or mouse anti-human IL-8 at 0.5 
μg/mL.  Number of branch points were quantified.  (B)  rh VEGF165 (2 ng/mL) or CM from purified human OCLs 
was added to the human endothelial cell / fibroblast in vitro angiogenesis assay after a 30 minute pre-incubation at 
the indicated concentrations with mouse IgG or mouse anti-human IL-8 at 1 μg/mL.  Mean  ± SEM. * p < 0.05 by 
ANOVA. 
 
We also tested whether MCP-1 might be an important OCL derived angiogenic factor 
because it was also highly expressed on the human OCL quantitative PCR array.  However, 
doses of MCP-1, including doses higher than could be obtained from OCL CM, failed to 
stimulate the human in vitro angiogenesis assay (Figure 3.11) 
 Thus, it seems unlikely that IL-8, MCP-1 or osteopontin at least by themselves are 
the key angiogenic factor in human OCL conditioned media.      
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 Figure 3.11.  Recombinant MCP-1 does not stimulate angiogenesis in vitro.  
rh MCP-1 added to human  fibroblast / HUVEC co-culture angiogenesis assay at doses indicated.  Mean ± 
SEM     
3.5 CONCLUSIONS 
In studies to examine the mechanism(s) responsible for OCL stimulation of angiogenesis 
we determined that MMP-9 plays an important role in OCL stimulation of angiogenesis, as well 
as bone remodeling, with both the angiogenic and bone resorptive effects of PTHrP being absent 
in MMP-9-/- metatarsal explants.  Similarly, the pro-angiogenic and bone resorptive effects of 
RANKL were reduced in MMP-9-/- calvaria in vivo.  The reduced angiogenesis seen in MMP-9-/- 
explants or mice treated with PTHrP or RANKL most probably reflects the decreased OCL 
numbers and activity in MMP-9-/- mice at the site where angiogenesis occurs, compared to WT 
controls.  The number of vessels per OCL was not different between genotypes, suggesting that 
OCLs lacking MMP-9 do not have an intrinsic angiogenic deficit once they have formed and 
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migrated to the proper location.  Similarly, PTHrP stimulated both angiogenesis and resorption 
in wild type bone explants, but did not stimulate either angiogenesis or resorption in explants 
lacking MMP-9.   
The observed reductions in stimulated OCL formation or function in MMP-9 mice-/- are 
most likely due to reduced OCL migration rather than direct effects of MMP-9 on OCL 
differentiation or matrix solubilization.  Explants from E17 MMP-9-/- mouse metatarsals but not 
more mature bones show a lower level of basal resorption but not OCL number, compared to 
wild type due to delayed OCL invasion of the primary ossification center (growth plate) rather 
than a requirement for MMP-9 in biochemical matrix solubilization.[161]  Likewise, MMP-9 is 
required for migration of OCL or OCL precursor cell lines in vitro.[253-255]  MMP-9-/- and WT 
mice did not display different levels of OCL formation in vitro, showing that the decreased 
resorption or OCL numbers in explants or in vivo was not due to defective differentiation or 
decreased precursor numbers.  Because of our observations that MMP-9 is important for both 
bone resorption and angiogenesis under conditions of increased osteoclastogenesis, it may be 
possible clinically to inhibit both bone destruction and angiogenesis with a MMP-9 inhibitor.  
These findings are summarized in Firure 3.12.    
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 Figure 3.12.  MMP-9 is important for osteoclast stimulated angiogenesis due to its effects on 
osteoclast migration. 
 
MMP-9 is predominantly expressed by OCLs in bone and is expressed at high levels, 
suggesting that the MMP-9 required for OCL stimulation of angiogenesis is secreted by OCLs 
themselves.  I speculated in the introductory chapter that OCLs may stimulate angiogenesis 
through MMP-9 or other proteinase mediated released of VEGF from extracellular matrix.  This 
molecular action of MMP-9 occurs in bone and is important for OCL recruitment into the 
primary ossification center.[161]  Further, MMP-9-/- mice have delayed vessel invasion into the 
primary ossification center.[14]  We investigated the possibility that OCLs stimulate 
angiogenesis by VEGF release by examining the level of VEGF in complex with its receptors in 
vivo with an antibody that specifically recognizes these complexes.  Our data that a minority of 
vessels in PTHrP-treated mice, and no vessels in RANKL-treated mice were positive for VEGF / 
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receptor complexes suggests that OCLs stimulate angiogenesis primarily by other processes.  
The molecule(s) that act on vessels directly as a result of OCL stimulation in vivo remain 
unclear.      
I investigated how OCLs may stimulate angiogenesis by secretion of an angiogenic 
factor, that acts directly on endothelial cells by analyzing the angiogenic factors important for 
angiogenic activity of OCL conditioned media.  I did not find that any of the OCL-derived 
angiogenic factors were important on their own for direct stimulation of endothelial cells.  
Tanaka et al have reported OCLs stimulate angiogenesis in cell culture, and attributed the 
activity of their conditioned media to osteopontin.[5]  They showed that rh osteopontin 
stimulated in vitro angiogenesis, which was neutralized by an antibody to αvβ3 integrin, and that 
a neutralizing antibody to osteopontin neutralized the angiogenic activity of OCL conditioned 
media.  However, in contrast to these results, I was unable to detect any pro-angiogenic effects of 
rh-osteopontin at doses up to 3 fold the reported dose.  The basis for these differences is 
unknown.  These investigators did not determine if OCL-secreted osteopontin contributed to 
angiogenesis in vivo.  Likewise I found that MMP-9 inhibition did not decrease the angiogenic 
activity of OCL conditioned media.  Therefore, OCL-derived MMP-9 is unlikely to stimulate 
angiogenesis by direct action on endothelial cells.  Similarly, recombinant IL-8 did not stimulate 
in vitro angiogenesis at doses attainable by OCL conditioned media, and an IL-8 neutralizing 
antibody did not inhibit the angiogenic activity of OCL conditioned media.  Likewise, 
recombinant MCP-1 did not stimulate in vitro angiogenesis at doses attainable by OCL 
conditioned media.  Therefore, IL-8 and MCP-1 are also unlikely to be responsible for the 
angiogenic activity of OCL conditioned media.      
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Because I found that MMP-9 is required for OCL stimulated angiogenesis predominantly 
due to its effects on OCL migration, it is likely that there are additional factors produced as a 
result of increased osteoclastogenesis that are important for vessel stimulation.  Three possible 
sources of these factors are diagrammed in Figure 3.13.   Most simply, OCLs may stimulate 
angiogenesis through direct secretion of an angiogenic factor (mechanism #1).  However, more 
complex mechanisms may also occur.  OCLs may stimulate angiogenesis by release of one of the 
many angiogenic factors stored in extracellular matrix (mechanism #2)  Alternatively, OCLs 
may require a linked osteoblastic response to stimulate angiogenesis or may stimulate expression 
of an angiogenic factor in osteoblasts or other cells (mechanism #3).  Since osteoblast-derived 
VEGF is clearly important for angiogenesis, osteoblasts and OCLs may cooperate to stimulate 
angiogenesis through OCL stimulation of osteoblastic production of VEGF.   
My findings that MMP-9 affects both angiogenesis and OCLs suggests 
osteoclastogenesis and angiogenesis are linked in some situations.  Linkage between OCLs and 
vessels occurs most likely in situations where OCL invasion is required such as fetal long bones 
before invasion of the growth plate, long bone fracture healing or our observed remodeling of 
calvaria induced by RANKL.  OCLs most likely invade from the periosteum in these situations.  
Such linkage between osteoblasts and angiogenesis occurs during development of long 
bones.[15]  Linkage between OCLs and vessel formation could result from endothelial cell 
stimulation of OCL formation.  Endothelial cells can increase OCL formation by several 
mechanisms including increased RANKL expression on their surface, thereby stimulating OCL 
formation when co-cultured with OCL precursors.[140]  Endothelial cells may also regulate the 
recruitment of OCL precursors to remodeling sites from the vascular compartment.[141]   
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 Figure 3.13.  Possible sources of direct acting angiogenic factors. 
 
In summary I have shown that OCLs contribute to angiogenesis in vitro and in vivo by a 
mechanism requiring MMP-9.  MMP-9 is important for OCL resorption and formation, likely 
due to its previously reported effects on OCL invasion or migration rather than differentiation or 
matrix solubilization.  OCL-stimulated angiogenesis is deserving of further study to more 
precisely define the molecular mechanism(s) involved and to identify the physiological and 
pathological settings in which OCL-stimulated angiogenesis plays a role.     
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4.0  GENERAL CONCLUSIONS AND FUTURE DIRECTIONS 
4.1 GENERAL CONCLUSIONS 
4.1.1 The Osteoclast Is an Angiogenic Cell in Bone 
I have shown in this dissertation that osteoclasts are important for bone angiogenesis in a 
bone organ culture system and an in vivo model.  Prior to these studies, a possible role for the 
osteoclast in angiogenesis was unclear, with no published reports that osteoclasts were involved 
in angiogenesis in vivo.  There were reports that osteoclast conditioned media stimulated 
angiogenesis in vitro published during the course of my studies.[5, 150].  However, two studies 
specifically reported that osteoclasts were not important for angiogenesis in vivo.[4, 149]  
Integrating our results with those in the literature suggests that osteoclasts are important for 
angiogenesis at some, but not all, anatomic sites.   
The studies reporting that osteoclasts were not important for angiogenesis in vivo used 
bisphosphonates and / or osteopetrotic (lacking osteoclasts) mice to abolish osteoclast activity, 
and analyzed developmental angiogenesis in mouse tail vertebrae or in the epiphysis of the 
tibia.[4, 149]  I did not observe any increase in angiogenesis with osteoclast stimulation with 
PTHrP in femorae, but did find a different pattern of vessels in the metaphysis adjacent to the 
growth plate.  I have not analyzed vertebrae for an angiogenic response to PTHrP treatment.  In 
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my in vivo studies using RANKL, I did not analyze sites other than the calvaria because the 
RANKL was injected locally.  In the discussion section of the paper reporting the phenotype of 
MMP-9-/- mice, the authors reported that the phenotype of osteopetrotic mice (lacking 
osteoclastes c-fos-/- and op/op) mirrored the phenotype of MMP-9-/- mice; lengthened growth 
plate and delayed vessel invasion on the metaphyseal side of the growth plate.  Of note, these 
investigators did not observe any angiogenic defects in epiphyses of MMP-9-/- or osteopetrotic 
mice.  Thus it is likely that the relationship of osteoclasts to angiogenesis is different in 
epiphyses and metaphyses.  Therefore, it must be determined at each bone site of interest if 
osteoclasts do or do not contribute to angiogenesis.   
Of note, in both the organ culture system and calvaria stimulated with RANKL, 
osteoclast-stimulated angiogenesis was accompanied by a large amount of tissue modeling or 
remodeling.  During the time course of the metatarsal cultures, osteoclasts invade the primary 
ossification center.  With supra-calvarial RANKL treatment, the angiogenesis occurred in areas 
where calcified tissue was replaced by non-calcified tissues resembling active periosteum.  This 
process is reminiscent of endochondral ossification, where osteoclasts and vessels invade from 
the periosteum.  Thus, physiological processes accompanied by changes in tissue composition 
are likely candidates for an important role of osteoclasts in angiogenesis. 
If osteoclasts do primarily stimulate angiogenesis in situations of tissue modeling or 
remodeling, they are likely to stimulate angiogenesis by complex mechanisms involving several 
cell types.  As discussed in Chapter 3, osteoclasts and osteoblasts may co-operate to stimulate 
angiogenesis, and angiogenesis and osteoclastogenesis may be linked in some situations due to 
endothelial cell stimulation of osteoclastogenesis.      
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4.1.2 MMP-9 Is Required for Osteoclast-Stimulated Angiogenesis 
Because MMP-9 is primarily expressed by osteoclasts in bone and is important for 
angiogenesis in fracture healing and endochondral ossification, I determined if MMP-9 was 
important for osteoclast-stimulated angiogenesis.[14, 164]  My results were similar in both 
experimental systems.  MMP-9 blunted both the pro-angiogenic effects and osteoclastogenic 
effect of osteoclast stimulatory agents in metatarsal explants treated with PTHrP and calvaria 
treated with RANKL.  The importance of osteoclastic MMP-9 for angiogenesis resulted 
primarily from its capacity to stimulate osteoclast migration, a capacity which was reported prior 
to my studies.[12, 253]  The number of vessels per osteoclast did not differ between genotypes.  
This suggests that lack of MMP-9 did not reduce angiogenesis in our studies because of an 
angiogenic defect intrinsic to the osteoclast, but because of a reduced number of osteoclasts at 
the angiogenic site.  Likewise, osteoclast differentiation in vitro was not inhibited by lack of 
MMP-9.  Thus, MMP-9 likely decreased the number of osteoclasts at the angiogenic site due to 
decreased migration rather than precursor number or differentiation.  In MMM-9-/- calvaria, there 
was a small increase in osteoclastogenesis but no increase in angiogenesis.  Therefore, future 
studies need to determine if an intrinsic, albeit minor, angiogenic defect of MMP-9-/- osteoclasts 
is present.  However, I cannot make this conclusion from the current data.     
4.2 FUTURE DIRECTIONS 
The studies presented in this dissertation are extremely novel and should fundamentally 
change the way that angiogenesis in bone is understood.  Thus, they open up many new avenues 
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for research.  Firstly, studies should be performed to extend the findings presented here.  In 
particular, studies are required to definitively show if the MMP-9 required for osteoclast-
stimulated angiogenesis is derived from osteoclasts themselves.  Also, a more definitive 
examination of the anatomic sites where osteoclasts are important for angiogenesis is required.  
Secondly, it is very important that the mechanisms used by osteoclasts to stimulate angiogenesis 
are worked out in more depth.  I have shown that MMP-9 is required for osteoclast-stimulated 
angiogenesis, but the molecule(s) which directly acts on endothelial cells has yet to be 
determined.  Lastly, because angiogenesis in bone is important to many disease processes, 
further studies based on this work may uncover novel therapeutic approaches, increase our 
understanding of pathophysiology or explain the effects of anti-osteoclast therapeutics.  Each of 
the sub-headings below could comprise a publication-sized unit.  Many of these studies could be 
performed using the experimental techniques established in this dissertation.   
4.2.1 Extension of Findings 
An important series of studies suggested by our observations that osteoclasts stimulate 
angiogenesis by a MMP-9 dependent mechanism would be to specifically knock out MMP-9 in 
the OCL and perform similar studies as were performed in Chapter 3.  These types of 
experiments would permit the determination if the lack of osteoclastic MMP-9 blunts the pro-
angiogenic effects of PTHrP on metatarsal explants or RANKL on calavaria.  We and others 
have shown that MMP-9 is primarily expressed by OCLs in bone.  Therefore, it is likely that the 
MMP-9 required for OCL-stimulated angiogenesis is secreted by OCLs themselves.  An OCL 
specific MMP-9 knockout would resolve this question.  Our laboratory created a mouse line 
expressing Cre-recombinase controlled by the TRAP promoter, which is expressed in OCL and 
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committed OCL precursors.  However, to our knowledge, no one has created a floxed MMP-9 
line, likely due to the viability of MMP-9-/- animals.  Therefore, to create an OCL-specific MMP-
9-/- mouse, the gene must be floxed and bred to the existing TRAP-Cre mouse line.  An OCL 
specific MMP-9-/- mouse may also benefit the study of additional anatomic sites where OCLs 
may be involved in angiogenesis.  In this dissertation, I examined OCL-stimulated angiogenesis 
in detail in calvaria, and to a limited extent in long bones, but not in vertebrae.        
Before the creation of an OCL-specific MMP-9 knockout, useful studies can be 
performed to further explore how OCLs play a role in angiogenesis.  We intended to further 
confirm that PTHrP stimulated angiogenesis in vivo because of its OCL stimulatory effects, by 
blocking osteoclastogenesis with osteoprotegerin (OPG) or RANK-Fc in PTHrP and vehicle 
treated animals. This will allow us to determine if PTHrP is able to stimulate angiogenesis in 
vivo in the absence of OCLs.  However, we were unable to acquire sufficient quantities of 
osteoprotegerin or RANK-Fc that was active in our in vivo system.  Commercially available 
OPG-Fc from R&D systems had minimal activity.  The only formulations of OPG-Fc or RANK-
Fc reported to be active in vivo were developed by Amgen.[279]  Unfortunately, Amgen declined 
to provide us with these reagents.  Similarly, PTHrP treatment of MMP-9-/- and wild type mice 
would show if MMP-9 is required for angiogenesis stimulated by PTHrP.  These studies are 
ongoing.  
In preliminary studies not presented here, an OCL-specific (TRAP promoter driven) 
transgenic mouse for the matrix proteinase ADAM8 had increased calvarial vessel density, but 
these studies are not yet confirmed.  These studies would support an angiogenic role for OCLs 
and suggest a role for ADAM-8 in OCL-stimulated angiogenesis.     
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To perform the studies described in this section, it will be necessary to secure a reliable 
source of RANKL that is active in vivo.  The mouse-RANKL-GST used in vivo in these studies 
was generously provided by Dr. F. Patrick Ross.  Dr. Ross may not be able to provide any 
additional RANKL.  We did not observe any OCL stimulation with a dose of 2 μg per mouse per 
day in a volume of 200 μl of rh RANKL from R&D Systems.  A dose of 2 μg (R&D Systems) or 
6 μg (Peprotech) of mouse RANKL per day for 3 days injected over the femur was used to 
locally stimulate osteoclastogenesis at that site.[280]  Therefore it is likely that some commercial 
formulations of RANKL will be active in our system.  Alternatively, a purification protocol for 
m RANKL-GST will have to be adopted.      
4.2.2 Further Mechanistic Studies 
Further dissection of the mechanisms responsible for osteoclast-stimulated angiogenesis 
is needed.  Is OCL secretion of osteopontin or a yet unidentified angiogenic factor that directly 
acts on vessels important for OCL-Stimulated angiogenesis in vivo?  Tanaka et al reported that 
osteopontin is required for the angiogenic activity of OCL conditioned media [5], but I was not 
able to replicate some of their findings.  Osteopontin may not be important for OCL-stimulated 
angiogenesis in vivo because it is a very abundant protein (2% of non collagenous protein) and is 
primarily produced by osteoblasts rather than OCLs.[221]  A possible role for osteopontin in 
OCL-stimulated angiogenesis in vivo or in organ culture could be tested by stimulating OCLs in 
mice or in metatarsals in wild type and osteopontin-/- mice and determining if lack of osteopontin 
blunted the pro-angiogenic effects.           
Alternatively, are there intermediary cell types that respond to OCL and in turn produce 
angiogenic factors, and which cells are these?  Osteoblastic production of VEGF is a reasonable 
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candidate for possible OCL-stimulated angiogenesis due to an intermediary cell type.  Osteoblast 
VEGF is well-known to be involved in angiogenesis in bone.[15]  OCLs may stimulate 
expression of an angiogenic factor such as VEGF in osteoblasts, or may increase angiogenesis 
induced by osteoblasts due to coupled bone formation.  I investigated a possible requirement for 
VEGF in OCL-stimulated angiogenesis by determining if metatarsal angiogenesis stimulated by 
PTHrP was blocked by a VEGF neutralizing antibody.  However, the VEGF neutralizing 
antibody greatly diminished the basal level of angiogenesis in the assay, making the results 
uninterpretable (data not shown).  However, a similar approach may be used in organ culture or 
in vivo with an existing line of mice specifically lacking HIF-1α in osteoblasts and thus having 
greatly reduced osteoblastic VEGF expression.  If osteoblastic VEGF is important for OCL-
stimulated angiogenesis, angiogenesis stimulated by PTHrP or RANKL should be blunted in 
studies employing these mice.   
Are angiogenic factors released from matrix important for the angiogenic potential of OCLs?  
Our studies suggest that OCL release of matrix bound VEGF is not primarily responsible for 
their ability to stimulate angiogenesis.  However, other factors, notable TGF-β, may be released 
by OCLs to stimulate angiogenesis.  TGF-β may stimulate angiogenesis directly or by induction 
of VEGF in osteoblasts.[216]  TGF-β is likely to come from calcified bone matrix.[10, 270]  
Therefore, the src-/- mouse, in which OCLs form but do not resorb bone may be used to study a 
possible role for calcified matrix resorption and TGF-β.[53]  These studies will have to be 
interpreted in light of possible effects of lack or src upon endothelial cells.        
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4.2.3 Role of Osteoclast-Stimulated Angiogenesis in Myeloma and Tumor Metastases 
Much of the current research into bone metastases has been influenced by the “vicious 
cycle” hypothesis.  In this model, tumor cells increase OCL formation by secreting factors such 
as IL-6.  The resultant increased numbers of OCLs increase tumor growth due to release of 
factors such as TGF-β from matrix.[109]  The increased numbers of OCLs induced by the tumor 
could increase angiogenesis.  However, increased angiogenesis could also result from the 
increased tumor burden.  Therefore, it is very challenging to directly study the contribution of 
OCL-stimulated angiogenesis to bone metastases.  The discovery of the importance of MMP-9 
for OCL-simulated angiogenesis may allow the more direct study OCL-stimulated angiogenesis 
in bone metastases.  Because MMP-9 is predominantly expressed by OCLs, the use of a host 
mouse lacking MMP-9 may allow the study of OCL-stimulated angiogenesis.  However, two 
studies suggest that this line of research may not yield dramatic results.  Host derived MMP-9 
has been reported to be important for angiogenesis (but not tumor burden) in a prostate xenograft 
model of bone metastasis.[281]  Similarly, a recent report found that host derived MMP-7, but 
not MMP-9 was important to increase tumor burden in a model of breast cancer bone metastases, 
but the authors did not study angiogenesis.[257]  Therefore, we will need to carefully consider 
the results of these studies before investing resources in the study of MMP-9 in bone metastases.  
If we decide to undertake these studies, we have techniques and models readily available.  OCLs 
may not need to migrate to stimulate angiogenesis in tumors, so MMP-9 may be less important 
for OCL-stimulated angiogenesis in this setting. 
If a OCL-specific MMP-9-/- mouse line is not created, we could study the effects of lack 
of host MMP-9 in two bone metastasis models: B16 melanoma ingrafted in genotype matched 
C57BL/6 or C57BL/6 MMP-9 -/-mice, and 5TGM multiple myeloma ingrafted in in RAG-1-/-, 
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MMP-9 -/- or RAG-1-/-, MMP-9+/+ mice.  Important parameters include angiogenesis, tumor 
burden and bone resorption.  We will be able to rapidly begin studies in the B16 model because 
the cells are of the same genetic background as the MMP-9-/- mice, which we have available, and 
concurrently establish a colony of RAG-1-/-, MMP-9-/- mice.  Myeloma metastasis will be 
established by two methods, intratibial, and supracalvarial injection, both of which have been 
used successfully in our laboratory.  We chose to examine the calvarial site in addition to the 
more commonly examined long bones, because of our data showing the importance of OCLs and 
MMP-9 to angiogenesis in calvaria.  In addition to its clinical relevance, myeloma is an 
interesting model to use to examine the contribution of OCL MMP-9 to angiogenesis because of 
the osteoblast suppression caused by myeloma cells.  In our previous studies, it has been difficult 
to determine if osteoblasts were also required for OCLs to stimulate angiogenesis.                     
4.2.4 Role of OCL-Stimulated Angiogenesis in Fracture Repair 
Osteoclasts are important for fracture healing as shown by delayed fracture healing or 
non-unions in osteopetrotic (ia/ia) rats or RANK-/- mice.[166, 282]  Furthermore, consistent with 
our findings, non-stabilized tibial fractures have less vessel density in RANK-/- than WT 
mice.[166]  Likewise, MMP-9-/- mice have increased numbers of non-unions and less vessel 
invasion of non-stabilized tibial fractures.  However, the source of MMP-9 at this site is 
especially uncertain due to MMP-9 expression by inflammatory cells.[164]  Thus, the literature 
suggests that osteoclast-derived MMP-9 is important for angiogenesis in fracture healing, and 
fracture healing in general.  The distinction between stabilized and non-stabilized fractures is 
important because non-stabilized fractures heal by way of a cartiliage intermediate, which is 
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invaded by vessels and OCLs in a similar fashion as the primary ossification center during 
development, and in the fetal metatarsal assay employed in this dissertation.   
If an OCL-specific MMP-9-/- mouse is created, it will be used in a tibial non-stabilized 
fracture model to determine if OCL-derived MMP-9 is important for angiogenesis and long bone 
fracture healing.  However, angiogenesis in membranous (flat) rather than long bone fractures is 
poorly understood.  Our results that RANKL stimulated angiogenesis is blunted in MMP-9-/- 
mice also suggests that OCL-derived MMP-9 is important for angiogenesis and fracture healing 
of membranous bone.  To test this hypothesis, we will examine angiogenesis and healing of the 
calvarial defect model in global or OCL specific MMP-9-/- mice.[283]  If OPG-Fc or RANK-Fc 
is available, we will also inhibit osteoclastogenesis, and determine if OCLs themselves are 
important for angiogenesis and fracture healing in membranous bone.          
4.2.5 Role of OCL –Stimulated Angiogenesis  in Bisphosphonate Treated Mice 
An understanding of OCL-stimulated angiogenesis is of great importance to 
understanding the mechanism of action of bisphosphonates.  Bisphosphonates are anti-resorptive 
agents first used for osteoporosis.  They have shown great efficacy in bone metastases, and 
inhibit tumor growth and angiogenesis in bone.[190]  Micro-molar concentrations of 
bisphosphonates inhibit endothelial cells in vitro.[191]  However, it is unclear if this mechanism 
of action of bishphonates is realistic in vivo because OCLs are exposed to much higher levels of 
the drugs than endothelial cells.[189]  Therefore, my findings that OCLs are important for bone 
angiogenesis, may help to explain why bisphosphonates are angiogenic in vivo.  Moreover, 
bisphosphonates have also been found to inhibit tumor angiogenesis stimulated by macrophage 
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derived MMP-9 in other tissues.[13, 284]  Therefore, bisphosphonates may inhibit OCL-
stimulated angiogenesis by inhibiting their migration as well as their survival or resorption.  
The in vivo models and techniques established in this dissertation could be used to 
determine if the anti-angiogenic effects of bisphosphonates are due to their effects on OCLs.  In 
vitro experiments with bisphosphonates are difficult to interpret, as the cell types affected by the 
drugs may be very different due to the pharmacokinetics and deposition of the drugs in bone 
matrix.  I found that zoledronate inhibits metatarsal angiogenesis and osteoclastogenesis in 
parallel at micro-molar concentrations.  However, it was difficult to determine if this was due to 
toxicity or specific effects on OCLs and endothelial cells (data not shown).  To address this 
question, if bisphosphonates block the angiogenic effects of PTHrP or RANKL in vivo, this 
would suggest that their anti-angiogenic effects are due at least in part to OCL inhibition.  
Interpretation of this study would require that bisphosphonates had no effect on vessels among 
the animals treated with the vehicle for PTHrP or RANKL.  Furthermore, to determine if 
bisphosphonates may inhibit OCL-stimulated angiogenesis by inhibiting OCL expression of 
MMP-9, their effects on OCL MMP-9 expression could be determined in vitro.  They should 
also be able to inhibit OCL-induced angiogenesis in vivo at the same doses required to inhibit 
MMP-9 expression.   
Bisphosphonates are associated with osteonecrosis of the jaw (ONJ), especially in cancer 
patients.  However, the mechanism by which they may cause ONJ is unknown.  A recent report 
from a phase III trial of the RANKL monoclonal antibody denosumab found a comparable 
number of cases of ONJ in denosumab and zoledronate treated groups (Amgen website, August 
3, 2009).  This suggests that OCL inhibition in general, rather than specific properties of 
bisphosphonates, may cause ONJ.  Bisphosphonate suppression of bone remodeling is one of the 
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most popular hypotheses for ONJ pathogenesis.[196]  Decreased angiogenesis due to 
bisphonates may also play role in ONJ.  Recently, ONJ was reported patients treated with the 
anti-VEGF antibody bevacizumab.[197]  Furthermore, a small retrospective study found more 
cases of ONJ in cancer patients treated with bisphosphonates and bevacizumab than 
bisphosphonates alone.[198]  ONJ is also linked to dental extraction or other surgery.  Because 
of their ability to inhibit remodeling of the callus of fixed fractures in long bones, 
bisphosphonates may also contribute to ONJ due to affects on healing of dental trauma, such as 
extraction.[167, 168]       
One could use the rat root socket healing after extraction model to study the possible 
importance of angiogenesis stimulated by OCLs and MMP-9 to pathogenesis of ONJ.  This 
model is beginning to be used as an approximation of ONJ pathogenesis.  Inhibition of OCLs or 
MMP-9 may inhibit both healing and angiogenesis in this model.  A specific MMP-9 
neutralizing antibody has been used in vivo, However, this may prove cost prohibitive.[285]  
Small molecules that are less specific for MMP-9 are available for in vivo use.[286]  If sufficient 
quantities of in vivo active OPG-Fc or RANK-Fc are available, the role of osteoclasts in root 
socket angiogenesis and healing could also be studied.   
In summary, osteoclasts stimulate angiogenesis and MMP-9 is important for this process.  
Future studies are needed to confirm and extend our findings in normal and pathological 
conditions associated with increased osteoclast number and activity.                   
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